var title_f37_46_38624="Fourniers gangrene";
var content_f37_46_38624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fournier's gangrene in a patient with diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotizing fasciitis of the perineum (Fournier's gangrene) can involve the scrotum. The infection can begin abruptly with severe pain and may spread rapidly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38624=[""].join("\n");
var outline_f37_46_38624=null;
var title_f37_46_38625="Nylidrin: Drug information";
var content_f37_46_38625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nylidrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Arlidin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator, Peripheral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Circulatory insufficiency:",
"     </b>",
"     Oral: 3-12 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4424749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Considered &ldquo;possibly effective&rdquo; for increasing blood supply to treat peripheral disease (arteriosclerosis obliterans, diabetic vascular disease, nocturnal leg cramps, Raynaud's disease, frost bite, ischemic ulcer, thrombophlebitis) and circulatory disturbances of the inner ear (cochlear ischemia, macular or ampullar ischemia, etc)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dizziness, nausea, orthostatic hypotension, palpitation, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13396764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Nylidrin has been evaluated for use as a tocolytic (Kurki, 1991).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F202776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arlidin (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nylidrin is a peripheral vasodilator; this results from direct relaxation of vascular smooth muscle and beta-agonist action. Nylidrin does not appear to affect cutaneous blood flow; it reportedly increases heart rate and cardiac output; cutaneous blood flow is not enhanced to any appreciable extent.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kurki T, Eronen M, Lumme R, et al, \"A Randomized Double-Dummy Comparison Between Indomethacin and Nylidrin in Threatened Preterm Labor,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1991, 78(6):1093-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38625/abstract-text/1945214/pubmed\" id=\"1945214\" target=\"_blank\">",
"        1945214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10176 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2A680BD67D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38625=[""].join("\n");
var outline_f37_46_38625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202784\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202779\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202780\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4424749\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202774\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202782\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299776\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202771\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13396764\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202776\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202767\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38626="Nummular eczema legs 2";
var content_f37_46_38626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nummular dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Coin-shaped\" patches and plaques are located on the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38626=[""].join("\n");
var outline_f37_46_38626=null;
var title_f37_46_38627="Azelaic acid: Drug information";
var content_f37_46_38627=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelaic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/34/18980?source=see_link\">",
"    see \"Azelaic acid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/30/9699?source=see_link\">",
"    see \"Azelaic acid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azelex&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg; Plus&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Finacea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Topical: Cream 20%: Apply a thin film to the affected area(s) twice daily, in the morning and evening; may reduce to once daily if persistent skin irritation occurs. Improvement in condition is usually seen within 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rosacea:",
"     </b>",
"     Topical: Gel 15%: Apply a thin layer to the affected area(s) of the face twice daily, in the morning and evening; reassess if no improvement after 12 weeks of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/30/9699?source=see_link\">",
"      see \"Azelaic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acne vulgaris: Adolescents &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azelex&reg;: 20% (30 g, 50 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Finacea&reg;: 15% (50 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Finacea&reg; Plus&trade;: 15% (50 g [DSC]) [contains benzoic acid; packaged with cleanser and lotion]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F138290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply a thin film and gently massage into to clean, dry skin; wash hands following application. Avoid the use of occlusive dressings or wrappings. For gel formulation, cosmetics may be applied after the gel has dried. Use only mild soaps or soapless cleansing lotion for facial cleansing. Not intended for intravaginal, ophthalmic, or oral use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelex&reg;: Treatment of mild-to-moderate inflammatory acne vulgaris",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Finacea&reg;: Treatment of inflammatory papules and pustules of mild-to-moderate rosacea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Burning/stinging/tingling (1% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Pruritus (gel: 1% to 6%), dry skin/peeling/scaling/xerosis (&le;5), erythema (&le;2%), irritation (&le;2%), acne (gel: &le;1%), contact dermatitis (&le;1%), edema (gel: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Asthma exacerbation, allergic reaction, dermatitis, herpes labialis exacerbation, hypertrichosis, iridocyclitis, rash, reddening, small depigmented spots, vitiligo depigmentation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azelaic acid or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypopigmentation: A few cases of hypopigmentation after use have been reported; monitor for changes in skin color.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation: Discontinue use if severe skin irritation or sensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gel: Reassess use if no improvement is seen after 12 weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; not for ophthalmic or vaginal use. Use of occlusive dressings or wrappings should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13276947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies following oral administration. Minimal systemic absorption (&lt;4%) occurs following topical administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F138295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends that caution be exercised when administering azelaic acid to nursing women. Minimal systemic absorption (&lt;4%) occurs following topical administration; a significant change from baseline azelaic acid levels in the milk is not expected.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F729746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gel: Foods and beverages that might provoke erythema, flushing, and blushing, such as spicy food, alcoholic beverages, and thermally hot drinks (including hot coffee and tea), should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F138294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Azelex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (30 g): $251.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Finacea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (50 g): $232.18",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acnean (TW);",
"     </li>",
"     <li>",
"      Acnederm Medicated Lotion (MY, SG);",
"     </li>",
"     <li>",
"      Ami (TW);",
"     </li>",
"     <li>",
"      Av F Aza Acne Foundation (ID);",
"     </li>",
"     <li>",
"      Azalea (KP);",
"     </li>",
"     <li>",
"      Azeclear (HK);",
"     </li>",
"     <li>",
"      Azel (TW);",
"     </li>",
"     <li>",
"      Azelan (BR);",
"     </li>",
"     <li>",
"      Aziderm (IN);",
"     </li>",
"     <li>",
"      Cutacelan (AR, CO, EC, PE, VE);",
"     </li>",
"     <li>",
"      Finacea (AU, BG, FR, GB, IE, MX, SE);",
"     </li>",
"     <li>",
"      Skinoderm (IL);",
"     </li>",
"     <li>",
"      Skinorem (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Skinoren (AT, BE, CH, CZ, DE, DK, EE, ES, FI, GB, GR, HK, HN, IE, IT, MY, NO, NZ, PH, PK, PL, PT, RU, SE, TH, TR, TW, ZA);",
"     </li>",
"     <li>",
"      ZA (TW);",
"     </li>",
"     <li>",
"      Zelface (ID);",
"     </li>",
"     <li>",
"      Zeliris (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azelaic acid is a dietary constituent normally found in whole grain cereals; can be formed endogenously. Exact mechanism is not known.",
"     <i>",
"      In vitro",
"     </i>",
"     , azelaic acid possesses antimicrobial activity against",
"     <i>",
"      Propionibacterium acnes",
"     </i>",
"     and",
"     <i>",
"      Staphylococcus epidermidis",
"     </i>",
"     . May decrease microcomedo formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Cream: ~3% to 5% penetrates stratum corneum; up to 10% found in epidermis and dermis; 4% systemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Topical: Healthy subjects: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9038 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38627=[""].join("\n");
var outline_f37_46_38627=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138303\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663156\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138338\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138305\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138320\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138306\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138288\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138336\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138293\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138280\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298802\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218206\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138285\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276947\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138308\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138295\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729746\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138294\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138296\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138279\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138292\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/34/18980?source=related_link\">",
"      Azelaic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/30/9699?source=related_link\">",
"      Azelaic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38628="Calcium citrate: Drug information";
var content_f37_46_38628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium citrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/15/24820?source=see_link\">",
"    see \"Calcium citrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/2/29733?source=see_link\">",
"    see \"Calcium citrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-C-Caps [OTC];",
"     </li>",
"     <li>",
"      Cal-Cee [OTC];",
"     </li>",
"     <li>",
"      Cal-Citrate&trade; 225 [OTC];",
"     </li>",
"     <li>",
"      Calcitrate [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osteocit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dosage is in terms of",
"     <b>",
"      elemental",
"     </b>",
"     calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-70 years, males: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/2/29733?source=see_link\">",
"      see \"Calcium citrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dosage is in terms of",
"     <b>",
"      elemental",
"     </b>",
"     calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: RDA: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Females: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Males &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Males &gt;70 years: 1200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-C-Caps: Elemental calcium 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Citrate&trade; 225: Elemental calcium 225 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:  (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Elemental calcium 200 mg [DSC], Elemental calcium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Cee: Elemental calcium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcitrate: Elemental calcium 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Citracal&reg; may be confused with Citrucel&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild hypercalcemia (calcium: &gt;10.5 mg/dL) may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     More severe hypercalcemia (calcium: &gt;12 mg/dL) is associated with confusion, delirium, stupor, and coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia, hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, anorexia, vomiting, abdominal pain, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Achlorhydria: Calcium absorption is impaired in achlorhydria; common in elderly. Citrate may be preferred because better absorbed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D: It is recommended to concomitantly administer vitamin D for optimal calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Taking calcium (&le;500 mg) with food improves absorption.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F144541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13333813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (200): $9.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     950 mg (100): $3.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1040 mg (1000): $90.09",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12873955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium: 8.5-10.5 mg/dL. Monitor plasma calcium levels if using calcium salts as electrolyte supplements for deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corrected total calcium = total serum calcium + 0.8 (4.0 - measured serum albumin)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F144538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calbo (TW);",
"     </li>",
"     <li>",
"      Calcite (KP);",
"     </li>",
"     <li>",
"      Calcival (MX);",
"     </li>",
"     <li>",
"      Citrokalcium (HN);",
"     </li>",
"     <li>",
"      Jia-Cal (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderates nerve and muscle performance via action potential excitation threshold regulation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Requires vitamin D",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8829 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38628=[""].join("\n");
var outline_f37_46_38628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144555\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144546\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144552\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144547\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144531\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144518\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144532\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144560\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144553\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144535\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144522\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298939\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144541\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333812\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333813\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323033\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12873955\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144538\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144521\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144534\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8829|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/15/24820?source=related_link\">",
"      Calcium citrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/2/29733?source=related_link\">",
"      Calcium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38629="Omalizumab: Drug information";
var content_f37_46_38629=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omalizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/15/34036?source=see_link\">",
"    see \"Omalizumab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=see_link\">",
"    see \"Omalizumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xolair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xolair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Monoclonal Antibody, Anti-Asthmatic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     SubQ: Dose is based on pretreatment IgE serum levels and body weight. Dosing should not be adjusted based on IgE levels taken during treatment or &lt;1 year following discontinuation of therapy; doses should be adjusted during treatment for significant changes in body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &ge;30-100 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-90 kg: 150 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;90-150 kg: 300 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;100-200 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-90 kg: 300 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;90-150 kg: 225 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;200-300 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-60 kg: 300 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;60-90 kg: 225 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;90-150 kg: 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;300-400 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-70 kg: 225 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;70-90 kg: 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;90 kg: Do not administer dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;400-500 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-70 kg: 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;70-90 kg: 375 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;90 kg: Do not administer dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;500-600 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-60 kg: 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;60-70 kg: 375 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;70 kg: Do not administer dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IgE &gt;600-700 units/mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-60 kg: 375 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;60 kg: Do not administer dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F203376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=see_link\">",
"      see \"Omalizumab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Children &ge;12 years: SubQ: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xolair&reg;: 150 mg [contains sucrose 145.5 mg; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089829.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089829.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection only; doses &gt;150 mg should divided over more than one site. Injections may take 5-10 seconds to administer. Administer only under direct medical supervision and observe patient for a minimum of 2 hours following administration of any dose given.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe, persistent allergic asthma not adequately controlled with inhaled corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9525624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Omalizumab may be confused with ofatumumab",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (45%; placebo 43%; severe 12%). Most reactions occurred within 1 hour, lasted &lt;8 days, and decreased in frequency with additional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (20%), sinusitis (16%), pharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (7%), fatigue (3%), dizziness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (2%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (8%), leg pain (4%), arm pain (2%), fracture (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia; anaphylaxis (angioedema of the throat or tongue, bronchospasm, chest tightness, cough, cutaneous angioedema, dyspnea, hypotension, generalized pruritus, syncope, and urticaria); antibody formation to omalizumab, hot flushes, malignancy (0.5%; placebo 0.2%), throat edema, thrombocytopenia, tongue edema, urticaria, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to omalizumab or any component of the formulation; acute bronchospasm, status asthmaticus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylaxis, including delayed-onset anaphylaxis, has been reported following administration; reactions usually occur within 2 hours of administration, but may occur up to 24 hours and in some cases &gt;1 year after initiation of regular treatment.",
"     </b>",
"     Patients should receive treatment only under direct medical supervision and be observed for a minimum of 2 hours following administration; appropriate medications for the treatment of anaphylactic reactions should be available. Hypersensitivity reactions may occur following any dose, even during chronic therapy; discontinue therapy following any severe reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignant neoplasms: Have been reported with use in short-term studies; impact of long-term use is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients at risk for parasitic infections: Use with  caution and monitor patients at risk for parasitic (helminth) infections; risk of infection may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroid therapy: Gradually taper corticosteroid therapy, do not discontinue abruptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For use in patients with a documented reactivity to a perennial aeroallergen and with symptoms uncontrolled using inhaled corticosteroids; not used to control acute asthma symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosing/IgE levels: Dosing is based on pretreatment IgE serum levels and body weight. IgE levels remain elevated up to 1 year following treatment, therefore, levels taken during treatment cannot be used as a dosage guide.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. IgG molecules are known to cross the placenta; use during pregnancy only if clearly needed. A registry has been established to monitor outcomes of women exposed to omalizumab during pregnancy or within 8 weeks prior to pregnancy (866-496-5247).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F203351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IgG is excreted in human milk and excretion of omalizumab is expected. Effects to nursing infant are not known; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Xolair Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $862.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylactic/hypersensitivity reactions, baseline IgE; FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; monitor for signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Xolair (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Omalizumab is an IgG monoclonal antibody (recombinant DNA derived) which inhibits IgE binding to the high-affinity IgE receptor on mast cells and basophils. By decreasing bound IgE, the activation and release of mediators in the allergic response (early and late phase) is limited. Serum-free IgE levels and the number of high-affinity IgE receptors are decreased. Long-term treatment in patients with allergic asthma showed a decrease in asthma exacerbations and corticosteroid usage.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow following SubQ injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 78 &plusmn; 32 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; IgG degradation by reticuloendothelial system and endothelial cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 26 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 7-8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily via hepatic degradation; intact IgG may be secreted in bile",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Casale TB, Condemi J, LaForce C, et al, &ldquo;Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 286(23):2956-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38629/abstract-text/11743836/pubmed\" id=\"11743836\" target=\"_blank\">",
"        11743836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38629/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcus P, &ldquo;Incorporating Anti-IgE (Omalizumab) Therapy Into Pulmonary Medicine Practice,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(2):466-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38629/abstract-text/16478867/pubmed\" id=\"16478867\" target=\"_blank\">",
"        16478867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milgrom H, Berger W, Nayak A, et al, &ldquo;Treatment of Childhood Asthma With Anti-immunoglobulin E Antibody (Omalizumab),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(2):E36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38629/abstract-text/11483846/pubmed\" id=\"11483846\" target=\"_blank\">",
"        11483846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milgrom H, Fick RB Jr, Su JQ, et al, &ldquo;Treatment of Allergic Asthma With Monoclonal Anti-IgE Antibody. rhuMAb-E25 Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(26):1966-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38629/abstract-text/10607813/pubmed\" id=\"10607813\" target=\"_blank\">",
"        10607813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10251 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38629=[""].join("\n");
var outline_f37_46_38629=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709181\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203365\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203382\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203366\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203376\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203367\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203343\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203329\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874749\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203345\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203344\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525624\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203380\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203348\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203333\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299788\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203339\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203350\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203370\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203351\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422269\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038711\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203332\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203347\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/15/34036?source=related_link\">",
"      Omalizumab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=related_link\">",
"      Omalizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38630="Aprepitant: Pediatric drug information";
var content_f37_46_38630=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aprepitant: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"    see \"Aprepitant: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/22/24932?source=see_link\">",
"    see \"Aprepitant: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5498119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13313097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Substance P/Neurokinin 1 Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13313106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"      see \"Aprepitant: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;11 years and Adolescents (&gt;40 kg):",
"     <b>",
"      Prevention of chemotherapy-induced nausea and vomiting:",
"     </b>",
"     125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a corticosteroid and 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist antiemetic) (Gore, 2009; Smith, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of chemotherapy-induced nausea and vomiting:",
"     </b>",
"     125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a corticosteroid and 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist antiemetic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of PONV:",
"     </b>",
"     40 mg within 3 hours prior to induction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild, moderate, or severe impairment: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis-dependent end-stage renal disease (ESRD): No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate impairment (Child-Pugh score 5-9): No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh score &gt;9): Use caution; no data available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg;: 40 mg, 80 mg, 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral [each package contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg;: Capsule: 80 mg (2s) and Capsule: 125 mg (1s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13313107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food, 1 hour prior to chemotherapy on day 1 of treatment and in the morning on the subsequent next 2 days or within 3 hours prior to induction of anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13313103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13313098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderate and highly emetogenic cancer chemotherapy (MEC &amp; HEC) (in combination with other antiemetic agents); prevention of postoperative nausea and vomiting (PONV) (FDA approved in ages &ge;18 years and adults).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5656106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aprepitant may be confused with fosaprepitant",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Emend&reg; (aprepitant) oral capsule formulation may be confused with Emend&reg; for injection (fosaprepitant)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported as part of a combination chemotherapy regimen or with general anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, epigastric discomfort, gastritis, nausea, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Acid reflux, acne, albumin decreased, alkaline phosphatase increased, anaphylactic reaction, anemia, angioedema, anxiety, appetite decreased, arthralgia, back pain, bilirubin increased, candidiasis, confusion, conjunctivitis, cough, deglutition disorder, depression, diabetes mellitus, diaphoresis, disorientation, duodenal ulcer (perforating), DVT, dysarthria, dysphagia, dyspnea, dysuria, edema, enterocolitis, eructation, erythrocyturia, febrile neutropenia, flatulence, flushing, glucosuria, herpes simplex, hyperglycemia, hypersensitivity reaction, hypertension, hypoesthesia, hypokalemia, hyponatremia, hypothermia, hypovolemia, hypoxia, leukocytes increased, leukocyturia, malaise, MI, miosis, muscular weakness, musculoskeletal pain, myalgia, nasal secretion, neutropenic sepsis, obstipation, pain, palpitation, pelvic pain, peripheral neuropathy, pharyngitis, pharyngolaryngeal pain, pneumonia, pneumonitis, pruritus, pulmonary embolism, rash, renal insufficiency, respiratory infection, respiratory insufficiency, rigors, salivation increased, sensory disturbance, sensory neuropathy, septic shock, Stevens-Johnson syndrome, syncope, tachycardia, taste disturbance, thrombocytopenia, toxic epidermal necrolysis, tremor, urinary tract infection, urticaria, visual acuity decreased, vocal disturbance, weight loss, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13313099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aprepitant or any component; concurrent use with pimozide, terfenadine, astemizole, or cisapride",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13313112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe hepatic impairment (Child-Pugh score &gt;9); use has not been studied. Use with caution in patients receiving medications metabolized by CYP3A4 as decreased metabolism and subsequent elevation of serum concentration may occur; the effect of aprepitant on orally administered CYP3A4 substrates may be greater than that seen with intravenously administered CYP3A4 substrates. A single 40 mg aprepitant oral dose in an adult is not likely to alter serum concentrations of CYP3A4 substrates. Use with caution and monitor closely in patients receiving docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine as they are known to be metabolized by CYP3A4 isoenzymes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic continuous use for prevention of nausea and vomiting is not recommended because it has not been studied. Aprepitant has not been studied for the treatment of established nausea and vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13313100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Aprepitant has the potential to significantly interact with many medications; increased serum concentrations of pimozide, terfenadine, astemizole, or cisapride could result in serious or life-threatening adverse effects. Concomitant use with warfarin may result in clinically significant decrease in INR; patients on warfarin should have INR monitored closely, particularly at 7-10 days following initiation of 3-day aprepitant therapy or a single 40 mg aprepitant oral dose in an adult for prevention of postoperative nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Efficacy of oral contraceptives may be reduced during treatment with aprepitant; alternative or additional methods of birth control should be used both during treatment with aprepitant and for at least 1 month following the last aprepitant dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (strong), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Aprepitant may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Aprepitant may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Aprepitant may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Aprepitant may decrease the serum concentration of Contraceptives (Progestins).  Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Aprepitant may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: Aprepitant may increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Aprepitant may decrease the serum concentration of PARoxetine. PARoxetine may decrease the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Aprepitant may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TOLBUTamide: Aprepitant may decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Aprepitant may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13313102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Aprepitant serum concentration may be increased when taken with grapefruit juice; avoid concurrent use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Use during pregnancy only if clearly needed.  Efficacy of hormonal contraceptive may be reduced; alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least 1 month following the last fosaprepitant/aprepitant dose.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13313104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 receptors. It augments the antiemetic activity of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists and corticosteroids to inhibit acute and delayed phases of chemotherapy-induced emesis. Aprepitant has little or no affinity for serotonin, dopamine, and corticosteroid receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13313105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~70 L; crosses the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 metabolites (weakly active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: ~9-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily via metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 62-90 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13313108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/22/24932?source=see_link\">",
"      see \"Aprepitant: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aprepitant may be taken with or without food; may cause dry mouth. Aprepitant may react with many other medications; report all medication use including OTC and herbal products to your physician. Avoid the herbal medicine St John's wort. Due to potential decreased effectiveness of oral contraceptives, alternative or additional contraceptive methods should be used during and for at least 1 month following therapy. Avoid grapefruit and grapefruit juice. Report unusual fatigue, weakness, dizziness, disorientation, abdominal discomfort, chest pain, or respiratory distress to your physician.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL oral aprepitant suspension may be prepared with capsules and a 1:1 combination of Ora-Sweet&reg; and Ora-Plus&reg; (or Ora-Blend&reg;). Empty the contents of four 125 mg capsules into a mortar and reduce to a fine powder (process will take 10-15 minutes). Add small portions of vehicle and mix to a uniform paste. Add sufficient vehicle to form a liquid; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 25 mL. Label \"shake well\" and \"refrigerate\". Stable for 90 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Dupuis LL, Lingertat-Walsh K, and Walker SE, \"Stability of an Extemporaneous Oral Liquid Aprepitant Formulation,\"",
"     <i>",
"      Support Care Cancer",
"     </i>",
"     , 2009, 17(6):701-6.",
"     <span class=\"pubmed-id\">",
"      19043742",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al, \"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38630/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choi MR, Jiles C, and Seibel NL, \"Aprepitant Use in Children, Adolescents, and Young Adults for the Control of Chemotherapy-Induced Nausea and Vomiting (CINV),\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2010, 32(7):268-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38630/abstract-text/20736848/pubmed\" id=\"20736848\" target=\"_blank\">",
"        20736848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gore L, Chawla S, Petrilli A, et al, \"Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(2):242-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38630/abstract-text/18985740/pubmed\" id=\"18985740\" target=\"_blank\">",
"        18985740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith AR, Repka TL, and Weigel BJ, \"Aprepitant for the Control of Chemotherapy Induced Nausea and Vomiting in Adolescents,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 45(6):857-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/46/38630/abstract-text/15849684/pubmed\" id=\"15849684\" target=\"_blank\">",
"        15849684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17055 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38630=[""].join("\n");
var outline_f37_46_38630=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498119\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313097\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313106\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136328\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313107\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313103\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313098\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5656106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136372\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313099\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313112\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313100\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136361\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313102\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313104\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313105\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313108\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806220\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=related_link\">",
"      Aprepitant: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/22/24932?source=related_link\">",
"      Aprepitant: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38631="Neuropsychiatric manifestations of systemic lupus erythematosus";
var content_f37_46_38631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuropsychiatric manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Shahram Khoshbin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38631/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/46/38631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system neuropsychiatric lupus refers to the various psychiatric and neurologic manifestations that develop secondary to involvement of the CNS in patients with systemic lupus erythematosus (SLE). These clinical features are characterized by some investigators as either diffuse (eg, encephalopathy, coma, depression, and psychosis) or complex (eg, encephalopathy with stroke or seizure, and psychiatric presentation with stroke or seizure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/1\">",
"     1",
"    </a>",
"    ]. Disturbances of mental function are the most common symptom.",
"   </p>",
"   <p>",
"    Because of the varied diagnostic criteria associated with these manifestations, the American College of Rheumatology (ACR) has formulated case definitions, reporting standards, and diagnostic testing recommendations for the 19 neuropsychiatric SLE syndromes (",
"    <a class=\"graphic graphic_table graphicRef51238 \" href=\"mobipreview.htm?6/40/6796\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/2\">",
"     2",
"    </a>",
"    ]. The full definitions can be found at the following Internet address:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/publications/ar/1999/aprilappendix.asp\">",
"     www.rheumatology.org/publications/ar/1999/aprilappendix.asp",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A psychiatric disturbance due to CNS lupus is a diagnosis of exclusion; all other possible causes of the observed symptoms must therefore be considered, including infection, electrolyte abnormalities, renal failure, drug effects, mass lesions, arterial emboli, and primary psychiatric disorders (such as bipolar disorder or severe stress disorder resulting from a chronic and life-threatening disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/3\">",
"     3",
"    </a>",
"    ]. One clue to the diagnosis is that most acute psychiatric episodes occur during the first two years after the onset of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term lupus cerebritis refers to the neuropsychiatric manifestations of lupus that appear to have an organic basis, rather than a specific pathophysiologic mechanism. The distinction between organic and functional causes of some neuropsychiatric symptoms can occasionally be made by assaying for specific autoantibodies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some investigators believe that a strong association exists between the occurrence of neuropsychiatric symptoms and the presence of antineuronal antibodies and other antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/6-9\">",
"       6-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiribosomal P antibodies have been associated with lupus psychosis and depression by some authors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. But this association has not been confirmed by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/9,12\">",
"       9,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27718?source=see_link\">",
"       \"Antiribosomal P protein antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some data suggest that cognitive defects may be associated with the presence of elevated levels of antineuronal antibodies, antiphospholipid antibodies, or antibodies to N-methyl-D-aspartate (NMDA) receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Others have not confirmed these observations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/9,16,17\">",
"       9,16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A functional (psychologic) process is assumed in a patient with cognitive defects who has none of these antibodies, a negative MRI and EEG, and psychometric testing that \"rules out\" organic disease.",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of the neuropsychiatric manifestations of CNS lupus will be reviewed here. Other neurologic manifestations of this disease and the diagnostic approach to neuropsychiatric lupus are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=see_link\">",
"     \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the American College of Rheumatology case definitions are used to determine the prevalence of neurologic and psychiatric manifestations the following order is noted (from most to least prevalent): cognitive dysfunction, headache, mood disorder, cerebrovascular disease, seizures, polyneuropathy, anxiety, and psychosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PSYCHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic psychosis occurs in approximately five percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], usually within the first year of diagnosis. As an example, one study of 36 patients with primary psychotic events found that 61 percent of the episodes occurred within the first year after the diagnosis of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/5\">",
"     5",
"    </a>",
"    ]. Recurrent episodes occurred in 10 patients at a median of eight months after the initial episode.",
"   </p>",
"   <p>",
"    Psychosis is characterized by disordered and bizarre thinking that often includes delusions and hallucinations. Some patients may also present with a fluctuating delirium or \"clouding of consciousness,\" typically occurring at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/20\">",
"     20",
"    </a>",
"    ]. Other associated symptoms include a poor attention span, easy distraction, misinterpretation of surroundings, agitation, or combative behavior.",
"   </p>",
"   <p>",
"    Symptoms may be caused by corticosteroid therapy or, more commonly, by CNS lupus. We have observed that auditory hallucinations are usually caused by steroid therapy, while visual and tactile disturbances are most frequently due to SLE. In the latter circumstance, an association has been noted between lupus psychosis and the presence of antibodies to ribosomal P protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/10\">",
"     10",
"    </a>",
"    ] or to neuronal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis due to (active) organic involvement by SLE usually responds to steroids. Treatment should be initiated as soon as possible to prevent permanent damage.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) given for a few weeks in divided doses is usually sufficient. If no improvement is seen within two to three weeks, a trial of cytotoxic therapy (eg, pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. One study, for example, evaluated the outcome in 31 patients with severe neuropsychiatric lupus who had primarily failed previous therapy with corticosteroids and, in some cases, oral cytotoxic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/23\">",
"     23",
"    </a>",
"    ]. The patients were treated with intravenous pulse cyclophosphamide and, in eight patients, plasmapheresis. Substantial improvement was seen in 61 percent and partial improvement in 29 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    may be an effective yet safer alternative to continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for long-term maintenance following recovery from an episode of psychosis. The potential value of such an approach was illustrated in an uncontrolled study of 13 patients with SLE whose psychosis was initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 8 weeks and then tapered); and oral cyclophosphamide (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/25\">",
"     25",
"    </a>",
"    ]. The initial prednisone and cyclophosphamide therapy was followed by azathioprine (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). The psychosis cleared in all patients within 7 months. During an average follow-up of 86 months on azathioprine maintenance, only one patient had a psychotic relapse.",
"   </p>",
"   <p>",
"    While waiting for steroids or immunosuppressive drugs to take effect, psychologic manifestations are best treated with typical antipsychotic drugs (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), as well as with active support by health caretakers and family. Oral or intramuscular administration is preferred to intravenous use because clinically significant prolongation of the QT interval may occur more often with the latter route. Use of atypical antipsychotics may be appropriate for patients with multiple risk factors for QT prolongation, including electrolyte imbalance, hypothyroidism, or use of other drugs associated with QT prolongation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COGNITIVE DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction is an organic mental syndrome characterized by any combination of the following symptoms: difficulty in short or long-term memory; impaired judgment and abstract thinking; aphasia; apraxia; agnosia; and personality changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. Cognitive defects are relatively common in patients with SLE, with an incidence ranging from 21 percent to 80 percent in studies using tests such as the Stanford-Binet Intelligence test, the Wechsler Adult Intelligence Scale, the Complex Attention Task, and the Pattern Comparison Task [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13,27-30\">",
"     13,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biologic mechanisms, cognitive assessment, and treatment of cognitive dysfunction has been reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/31\">",
"     31",
"    </a>",
"    ]. The following generalizations can be made regarding the clinical and pathophysiologic characteristics of patients with cognitive defects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is disagreement regarding the association between cognitive dysfunction, and the antibodies implicated in other types of neuropsychiatric CNS lupus. Some studies have found no difference in prevalence of either antineuronal or antiphospholipid antibodies between patients with cognitive dysfunction and normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/6\">",
"       6",
"      </a>",
"      ], while others have found an association with these antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13,14,32-34\">",
"       13,14,32-34",
"      </a>",
"      ]. Antibodies to ribosomal P protein have been associated with lupus psychosis and depression but not with cognitive dysfunction or psychological distress as assessed by the MMPI test (Minnesota Multiphasic Personality Inventory) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of cytokines, matrix metalloproteinases, vascular abnormalities, neuropeptides, and endocrine factors have been investigated; no consistent abnormalities have been noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive dysfunction appears to be evanescent, and is not directly correlated with active disease or corticosteroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13,28,35,36\">",
"       13,28,35,36",
"      </a>",
"      ]. However, it is more common in patients with active disease who are receiving corticosteroids&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/33,37\">",
"       33,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although it may occur independent of psychologic stress, cognitive dysfunction may be caused or exacerbated by a coexistent psychiatric disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13,35,38,39\">",
"       13,35,38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two patterns of memory dysfunction have been identified; impaired remote memory appears to be associated with a history of past CNS involvement (suggesting the presence of a residual neurologic deficit), while impaired immediate memory and concentration implies increased disease activity that may represent transient and diffuse CNS effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associated conditions such as hypertension, multiple small infarcts, and a variety of medications may produce cognitive dysfunction.",
"     </li>",
"     <li>",
"      Regular use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may help prevent cognitive decline, particularly in older patients. A beneficial effect of aspirin was seen in a prospective cohort study of 123 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/33\">",
"       33",
"      </a>",
"      ]. However, aspirin use was determined by patient and physician preference and clinical trials are needed to assess the efficacy and safety of this approach. However, the beneficial effects of aspirin on the incidence of cardiovascular events in the general population are well established. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic factors may play a role in susceptibility to cognitive dysfunction in SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/31,41\">",
"       31,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neuroimaging of patients with cognitive dysfunction has been an area of active investigation; as yet, none of the available imaging techniques have been predictive of cognitive impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is based upon the presumed etiology of the cognitive abnormalities. If due to medications, such as steroids, consider reducing the dose or stopping therapy. If associated with antiphospholipid antibodies, begin anticoagulation. If associated with antineuronal antibodies, a short course of steroids (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for a few weeks) may be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/42\">",
"     42",
"    </a>",
"    ]. Cognitive retraining using a combination of functional strategy training and psychosocial support may be effective in patients with persistent symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The result of a prospective study cited above suggests that regular use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may help prevent a decline in cognitive function, particularly in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/33\">",
"     33",
"    </a>",
"    ]. Use of aspirin should also be considered for prevention of cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Criteria for response to treatment of cognitive impairment have been proposed for use in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/44\">",
"     44",
"    </a>",
"    ]. A quantitative measure of cognitive function may be obtained using a combination of formal assessments (eg, the ACR neuropsychological battery and the Cognitive Symptoms Inventory). Serial assessments of cognitive function can also be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia is characterized by severe cognitive dysfunction, resulting in impaired memory, abstract thinking, and a decreased ability to perform simple manual tasks. The patient may also have difficulty making decisions or controlling impulses. This syndrome in patients with lupus can reflect multiple small ischemic strokes caused by antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact therapeutic regimen is unclear. Although symptoms occasionally abate without treatment, the following general recommendations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dementia due to multiple cerebral infarctions may be worsened by high dose corticosteroids. Consideration should be given to discontinuing or lowering the dose of corticosteroids and other medications that may aggravate symptoms, including nonsteroidal antiinflammatory drugs, antimalarial drugs, and antianxiety drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coexisting depression should be treated by conventional means.",
"     </li>",
"     <li>",
"      One small randomized, controlled study showed a statistically significant improvement in cognition in women with mild SLE treated with low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/42\">",
"       42",
"      </a>",
"      ]. Although these results are not directly applicable to dementia, we recommend a trial using the same regimen if the above modalities are ineffective.",
"     </li>",
"     <li>",
"      Support by family and health professionals, plus reminder prompts, will usually help patients deal with this problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SECONDARY PSYCHIATRIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although depression, anxiety and manic behavior may occasionally reflect organic involvement, these symptoms are more typically functional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/48\">",
"     48",
"    </a>",
"    ]. The distinction between organic and functional disease is based upon psychological testing, followed by a series of studies that may include CT scan, magnetic resonance imaging, SPECT scans, evoked potentials, electroencephalograms, cerebrospinal fluid analysis, and a psychiatric interview when the initial studies are equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/26,38\">",
"     26,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=see_link\">",
"     \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific psychologic symptoms that occur may include phobias, depression, anxiety, mania, paresthesias, headaches, mood swings, agoraphobia (with and without panic), social phobia, alcohol abuse, cognitive problems such as poor concentration, impaired memory, and difficulty with word finding or spatial orientation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13,49\">",
"     13,49",
"    </a>",
"    ]. The individual pattern that develops usually reflects the patients coping mechanisms used to deal with the stress of chronic illness, rather than a specific disease process.",
"   </p>",
"   <p>",
"    Interactions between the patient and physician can occasionally adversely effect symptom resolution. Patients often relate a long history of frustration in obtaining the proper diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/14\">",
"     14",
"    </a>",
"    ], and physicians may have difficulty dealing with patients who have neuropsychiatric symptoms and signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common psychologic symptom in patients with SLE is depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/30,51,52\">",
"     30,51,52",
"    </a>",
"    ]. Depressive symptoms usually begin acutely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/53\">",
"     53",
"    </a>",
"    ]. They reflect the patient's reaction to chronic illness and the significant lifestyle limitations that must be endured, including difficulties with pregnancy, fatigue, limited sun exposure, and chronic medication use,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coping styles and limited social support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. There may also be an organic basis in some cases. Some depressed patients, for example, have elevated levels of certain autoantibodies or are more prone to have associated illnesses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An association has been reported between severe depression and anti-ribosomal P antibodies, and antibodies to NMDA-receptors, but not with other antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/1,16,53,54\">",
"       1,16,53,54",
"      </a>",
"      ]. Elevated levels of antibodies to ribosomal P proteins have been found in 70 to 88 percent of such patients by some investigators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/1,54\">",
"       1,54",
"      </a>",
"      ]; others have failed to observe an association between depression and antibodies to NMDA-receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study of 71 patients with SLE noted an association between depression and both neuropsychiatric lupus and secondary Sj&ouml;gren's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients with neuropsychiatric lupus had an adjusted odds ratio of 3.43 for depressive symptoms, while those with secondary Sj&ouml;gren's syndrome had an adjusted odds ratio of 2.97.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients recover within one year with the help of family, friends, physicians,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other professionals. Other patients may incorporate the depression into their personality, thereby developing many concurrent (psycho)somatic complaints such as insomnia, anorexia, constipation, myalgia, arthralgia, and fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Patients may also develop \"psychotic\" features, with increasing despair, loss of hope, and even suicidal tendencies; prompt psychiatric intervention is essential in this circumstance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial diagnosis of SLE, or after an acute exacerbation, some patients display symptoms of anxiety, either instead of or in addition to depression. The patient may become anxious about a variety of possible consequences of their illness, including disfigurement, disability, dependency, loss of a job, social isolation, or death.",
"   </p>",
"   <p>",
"    Anxiety may be manifested by palpitations, diarrhea, sweating, hyperventilation, dizzy spells, difficulty with speech, memory, or words, fear of \"going crazy,\" or headaches. This state may deteriorate into obsessive-compulsive behavior, phobias, hypochondriasis, sleep disturbances, and a reduction in social contacts and interaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other psychiatric manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop manic behavior or an organic personality disorder. The former is characterized by a marked increase in energy and activity, irritability, and sleeplessness. This behavior is usually due to high doses of steroids. A sudden marked change in personality may also occur due to any of the causes discussed above, with symptoms including apathy, indifference, emotional lability, sexual indiscretions, verbosity, religiosity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aggressiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38631/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/1\">",
"      West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/2\">",
"      The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/3\">",
"      Miguel EC, Pereira RM, Pereira CA, et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine (Baltimore) 1994; 73:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/4\">",
"      Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/5\">",
"      Ward MM, Studenski S. The time course of acute psychiatric episodes in systemic lupus erythematosus. J Rheumatol 1991; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/6\">",
"      Hanly JG, Fisk JD, Eastwood B. Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. Lupus 1994; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/7\">",
"      Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/8\">",
"      Denburg JA, Behmann SA. Lymphocyte and neuronal antigens in neuropsychiatric lupus: presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity. Ann Rheum Dis 1994; 53:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/9\">",
"      Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004; 6:R366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/10\">",
"      Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/11\">",
"      Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996; 39:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/12\">",
"      Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/13\">",
"      Carbotte RM, Denburg SD, Denburg JA. Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Arthritis Rheum 1995; 38:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/14\">",
"      Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/15\">",
"      Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/16\">",
"      Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/17\">",
"      Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/18\">",
"      Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004; 13:861.",
"     </a>",
"    </li>",
"    <li>",
"     Rogers, MP. Psychiatric Aspects. In: The Clinical Management of Systemic Lupus Erythematosus (Second Edition), Schur, PH (Ed), Lippincott, Philadelphia 1996.",
"    </li>",
"    <li>",
"     Perry, SW. Psychiatric aspects of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Lahita, RG (Ed), John Wiley and Sons, New York, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/21\">",
"      Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981; 70:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/22\">",
"      Schroeder JO, Euler HH, L&ouml;ffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987; 107:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/23\">",
"      Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/24\">",
"      Boumpas DT, Yamada H, Patronas NJ, et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/25\">",
"      Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115:59.",
"     </a>",
"    </li>",
"    <li>",
"     Rogers, MP, Liang, MH, Waterhouse, E, et al. Disturbed cognition and systemic lupus erythematosus: A subset of central nervous system lupus. Submitted for publication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/27\">",
"      Hay EM. Psychiatric disorder and cognitive impairment in SLE. Lupus 1994; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/28\">",
"      Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1994; 21:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/29\">",
"      Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/30\">",
"      Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006; 55:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/31\">",
"      Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008; 58:3286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/32\">",
"      Menon S, Jameson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/33\">",
"      McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005; 64:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/34\">",
"      Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/35\">",
"      Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/36\">",
"      Hay EM, Black D, Huddy A, et al. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992; 35:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/37\">",
"      Hanly JG, Fisk JD, Sherwood G, et al. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992; 19:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/38\">",
"      Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/39\">",
"      Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994; 53:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/40\">",
"      Fisk JD, Eastwood B, Sherwood G, Hanly JG. Patterns of cognitive impairment in patients with systemic lupus erythematosus. Br J Rheumatol 1993; 32:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/41\">",
"      Oroszi G, Lapteva L, Davis E, et al. The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/42\">",
"      Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/43\">",
"      Harrison MJ, Morris KA, Horton R, et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 2005; 65:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/44\">",
"      Ad Hoc Committee on Lupus Response Criteria: Cognition Sub-committee, Mikdashi JA, Esdaile JM, et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007; 16:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/45\">",
"      West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/46\">",
"      Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/47\">",
"      Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/48\">",
"      Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/49\">",
"      L&iacute;ndal E, Thorlacius S, Steinsson K, Stef&aacute;nsson JG. Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol 1995; 24:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/50\">",
"      Goodwin JM, Goodwin JS, Kellner R. Psychiatric symptoms in disliked medical patients. JAMA 1979; 241:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/51\">",
"      Kozora E, Ellison MC, Waxmonsky JA, et al. Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005; 14:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/52\">",
"      Jump RL, Robinson ME, Armstrong AE, et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005; 32:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/53\">",
"      Shortall E, Isenberg D, Newman SP. Factors associated with mood and mood disorders in SLE. Lupus 1995; 4:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/54\">",
"      Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/55\">",
"      Utset TO, Golden M, Siberry G, et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sj&ouml;gren's syndrome. J Rheumatol 1994; 21:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/56\">",
"      McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 1995; 38:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38631/abstract/57\">",
"      Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990; 17:1450.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4863 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38631=[""].join("\n");
var outline_f37_46_38631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PSYCHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COGNITIVE DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SECONDARY PSYCHIATRIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other psychiatric manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/40/6796\" title=\"table 1\">",
"      ACR neuropsychiatric SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=related_link\">",
"      Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38632="Aspiration due to swallowing dysfunction in infants and children";
var content_f37_46_38632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aspiration due to swallowing dysfunction in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Okan Elidemir, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Leland L Fan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38632/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/46/38632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H367105855\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is defined as the entry of foreign material into the airway below the true vocal cords. In normal individuals, particularly infants and children, aspiration occurs when the airway protective mechanisms are stressed, such as while talking, laughing, eating, or sleeping. In most instances, an inconsequential amount of material is aspirated. In contrast, children with swallowing dysfunction are at much greater risk for pathologic aspiration. In these individuals, aspiration may result in acute or chronic pulmonary compromise, and impaired nutritional intake may lead to failure to thrive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105375\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF FEEDING AND SWALLOWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The swallowing mechanism goes through stages of maturation during infancy, beginning with suckling movements in utero and progressing to the development of chewing during early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Recognition of these developmental states informs the evaluation of swallowing disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suckling, the earliest form of sucking, is characterized by a primitive anterior to posterior movement of the tongue. Suckling movements begin in utero with suckling and swallowing of amniotic fluid, and are the main form of feeding activity during the first four to six months of life. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=see_link\">",
"       \"Sucking and swallowing disorders in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      True suck is usually established by nine months of age.",
"     </li>",
"     <li>",
"      The ability to drink from a cup requires both sucking and swallowing, and is usually established by 12 months of age.",
"     </li>",
"     <li>",
"      Chewing patterns develop gradually during infancy, with the establishment of true chewing by 24 months of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deglutition is another skill that develops as oropharyngeal structure and function mature. This process is typically divided into four phases: oral preparatory, oral, pharyngeal, and esophageal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The oral preparatory and oral phases, considered voluntary stages of swallowing, include receiving the food, forming the bolus, and transporting it posteriorly.",
"     </li>",
"     <li>",
"      The pharyngeal phase, also known as \"reflex swallow,\" utilizes complex and coordinated muscle activity. During this phase, contraction of the pharyngeal musculature propels the bolus downwards and the larynx elevates and closes at the level of the epiglottis, mainly by closure of the aryepiglottic folds and vocal cords, to prevent laryngeal penetration and aspiration.",
"     </li>",
"     <li>",
"      The cricopharyngeal sphincter relaxes to initiate the esophageal phase, during which the bolus passes through the esophagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105383\">",
"    <span class=\"h1\">",
"     CAUSES OF SWALLOWING DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of anatomical and functional disorders may predispose to swallowing abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367106155\">",
"    <span class=\"h2\">",
"     Anatomic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic abnormalities associated with swallowing dysfunction include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cleft",
"      <span class=\"nowrap\">",
"       lip/palate",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=see_link\">",
"       \"Facial clefts and holoprosencephaly\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Choanal atresia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"       \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Micrognathia (eg, Pierre-Robin syndrome, craniofacial dysostosis) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=see_link&amp;anchor=H4#H4\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Micrognathia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=see_link\">",
"       \"Syndromes with craniofacial abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharyngeal tumors and cysts (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=see_link&amp;anchor=H18#H18\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Oral cavity anomalies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laryngeal cleft (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=see_link&amp;anchor=H13#H13\">",
"       \"Congenital anomalies of the larynx\", section on 'Laryngeal clefts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tracheoesophageal fistula (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H16#H16\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheoesophageal fistula and esophageal atresia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Esophageal anomalies (eg, vascular rings, strictures, achalasia) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=see_link\">",
"       \"Clinical manifestations and diagnosis of achalasia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367106162\">",
"    <span class=\"h2\">",
"     Functional disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional disorders associated with swallowing dysfunction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed maturation (eg, Down syndrome, prematurity) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23912?source=see_link&amp;anchor=H16#H16\">",
"       \"Growth management in preterm infants\", section on 'Poor oral feeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain damage (eg, cerebral palsy, intrauterine infections, birth",
"      <span class=\"nowrap\">",
"       trauma/asphyxia,",
"      </span>",
"      intracranial hemorrhage,",
"      <span class=\"nowrap\">",
"       encephalitis/meningitis)",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=see_link\">",
"       \"Etiology and pathogenesis of neonatal encephalopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cranial nerve palsy, especially of CN IX and X (eg, poliomyelitis, meningitis, or central nervous system mass) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40569?source=see_link\">",
"       \"Evaluation of dysphagia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=see_link&amp;anchor=H10929015#H10929015\">",
"       \"Detailed neurologic assessment of infants and children\", section on 'Cranial nerves'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inherited neuromuscular diseases, including spinal muscular atrophy, familial dysautonomia, myotonic dystrophy, and myasthenia gravis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8344?source=see_link\">",
"       \"Spinal muscular atrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=see_link\">",
"       \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link\">",
"       \"Neuromuscular junction disorders in newborns and infants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367106177\">",
"    <span class=\"h2\">",
"     Iatrogenic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain therapeutic procedures may disrupt normal swallowing function, including local anesthesia to the pharynx or the presence of orogastric or nasogastric tubes. Tracheostomy can also interfere with swallowing function by impairing laryngeal elevation and shortening vocal cord closure time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105391\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swallowing dysfunction may present with a wide variety of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with swallowing dysfunction may display a weak suck, gagging, choking, disruptions in breathing, apnea, and cyanosis during feeding. Recurrent and chronic stridor may be present in some cases. Feeding difficulties may cause inadequate caloric intake and lead to failure to thrive.",
"   </p>",
"   <p>",
"    Coughing during feeding is a prominent symptom in most children who aspirate food into the tracheobronchial tree. However, the cough reflex may become blunted with repeated aspiration. Thus, silent aspiration may occur",
"    <strong>",
"    </strong>",
"    without identifiable cough during feeding, and is particularly common among children with underlying neurologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, infants are less likely to cough with aspiration as compared to older children, because of developmental differences in laryngeal chemoreflexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children have symptoms and signs of recurrent aspiration even when they are not fed by mouth, because of recurrent aspiration of the saliva. This pattern is particularly common among children with marked sialorrhea, choking on secretions, severe neurological impairment, vocal cord paralysis, and syndromic disorders of the nasopharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27705093\">",
"     'Salivary aspiration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other symptoms of laryngeal penetration include the sound of &ldquo;wet breathing&rdquo; or &ldquo;wet voice&rdquo;. Repeated aspiration may lead to recurrent wheezing; recurrent pneumonias, particularly in the dependent parts of the lungs; bronchiectasis due to repeated infections; and interstitial lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105399\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105407\">",
"    <span class=\"h2\">",
"     Videofluoroscopic modified barium swallow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The videofluoroscopic modified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow (MBS), also known as the videofluoroscopic swallow study (VFSS), is the procedure of choice for evaluating the pharyngeal and esophageal phases of deglutition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,10-13\">",
"     1,10-13",
"    </a>",
"    ]. It is generally performed after a clinical evaluation of swallowing by a speech-language pathologist, and the radiographic findings are interpreted in conjunction with the clinical findings. The procedure requires the presence and collaboration of a speech-language pathologist and radiologist in most settings. If the child has a nasogastric tube (NGT) it usually can be left in place; NGTs tend to slow several phases of swallowing but do not otherwise disturb swallowing function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this technique,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    is given to the patient orally, and swallowing is filmed from a lateral and anteroposterior view. The examination is focused on the oropharynx and proximal esophagus, and does not include views of the distal esophagus or stomach (",
"    <a class=\"graphic graphic_figure graphicRef59802 \" href=\"mobipreview.htm?4/16/4358\">",
"     figure 1",
"    </a>",
"    ). A variety of food textures mixed with barium (liquid, paste, and solid) are commonly employed to assess swallowing function. Contrary to popular belief, thin liquids are not the only primary substances aspirated; consistencies other than liquid are aspirated in many predisposed children, emphasizing the necessity of using varying textures of contrast material during MBS to increase its sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/15\">",
"     15",
"    </a>",
"    ]. Multiple swallows should be assessed because abnormalities may develop as the patient fatigues, particularly in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/16\">",
"     16",
"    </a>",
"    ]. In some cases, the feeding is continued without fluoroscopy to allow the infant to fatigue; then fluoroscopy is resumed to assess additional swallows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MBS is interpreted in real time by a speech-language pathologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologist with special training in the technique. The examiner can assess the duration of oral and pharyngeal transit time, characterize pharyngeal motility, and detect swallowing abnormalities including pooling of material in the vallecula and pyriform sinuses, residue in the pharyngeal recesses, and aspiration into the tracheobronchial tree. Although the presence of contrast material in the tracheobronchial tree is diagnostic of aspiration, it may not be detected during a single MBS study, due to the intermittent and sporadic nature of aspiration. Thus, the specificity of this test for aspiration is high but its sensitivity is low.",
"   </p>",
"   <p>",
"    Nasopharyngeal reflux, cricopharyngeal dysfunction, and laryngeal penetration are commonly observed abnormalities (",
"    <a class=\"graphic graphic_table graphicRef51330 \" href=\"mobipreview.htm?35/28/36299\">",
"     table 1",
"    </a>",
"    ). The presence of any of these findings may be due to maturational process in young infants but is abnormal in children over one year of age; they indicate swallowing dysfunction but do not correlate well with aspiration. Healthy infants may have laryngeal penetration due to an immature swallowing mechanism, which resolves by one year of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/15\">",
"     15",
"    </a>",
"    ]. In older children and adults, there is a high correlation between deep laryngeal penetration noted on MBS and aspiration into the tracheobronchial tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/17\">",
"     17",
"    </a>",
"    ]. The frequency, nature, and severity of clinical symptoms must be taken into consideration while making treatment decisions based",
"    <strong>",
"    </strong>",
"    on the results of MBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105422\">",
"    <span class=\"h2\">",
"     Fiberoptic endoscopic examination of swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiberoptic endoscopic examination of swallowing (FEES) utilizes a fiberoptic laryngoscope positioned above the palate, through which an endoscopist can directly assess laryngeal elevation and closure during the swallowing. In addition, coloring the food bolus permits evaluation of residual pooling and aspiration.",
"   </p>",
"   <p>",
"    This technique is commonly employed in adults, and good correlations with MBS have been shown. This technique is used infrequently in children due to its invasive nature and lack of standardization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. It does have the advantage of avoiding ionizing radiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\", section on 'Fiberoptic endoscopic evaluation of swallowing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105430\">",
"    <span class=\"h2\">",
"     Gastroesophageal scintigraphy and salivagram",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are nuclear medicine scans in which small amounts of technetium-99m are either mixed with milk and given to the patient to drink (gastroesophageal scintigraphy, also known as a &ldquo;milk scan&rdquo;) or directly instilled into the mouth (salivagram). Gamma camera images of the chest are taken at intervals for up to 24 hours, with detection of radioactivity in lung fields considered a positive test.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastroesophageal scintigraphy &ndash; This test is designed primarily to measure aspiration of stomach contents after reflux from the stomach (retrograde aspiration). If appearance of tracer in the lungs is considered positive, only 6 to 23 percent of patients that undergo gastroesophageal scintigraphy have positive results even when other clinical or radiographic indicators of aspiration are positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Therefore, the sensitivity of this test for detecting clinically important aspiration appears to be low. A few studies report appearance of tracer in the esophagus instead of tracer in the lungs; these studies report up to 40 percent &ldquo;positive&rdquo; scans, but the correlation with clinical or other radiographic measures of aspiration is poor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/21\">",
"       21",
"      </a>",
"      ]. Therefore, gastroesophageal scintigraphy has limited value for detecting clinically important aspiration, and is infrequently used in clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Salivagram &ndash; This test is designed to detect aspiration during swallowing (antegrade aspiration). Among patients referred for evaluation of aspiration and swallowing, a high proportion have positive salivagrams (16 to 56 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]). In one study, there was close correlation between positive findings on salivagram and abnormalities on chest radiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/22\">",
"       22",
"      </a>",
"      ]. Among subjects with a positive salivagram, 90 percent had abnormalities on chest radiography, giving a strong clinical suspicion for aspiration. All of the remaining 10 percent of subjects with &ldquo;false positive&rdquo; results (positive salivagram but normal chest radiography) were younger than one year of age. In a separate study of neurodevelopmentally normal children with recurrent lower respiratory tract infections, salivagrams were more likely to be positive in infants (40 percent) as compared with children one to two years of age (16 percent) and older children (0 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/21\">",
"       21",
"      </a>",
"      ]. Thus, there is preliminary evidence that an abnormal salivagram is associated with clinical respiratory problems in referral populations, but the association may be weaker in infants and toddlers because of more false-positive results in this young age group. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105438\">",
"    <span class=\"h2\">",
"     Lipid-laden macrophages",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pediatric studies have suggested that the detection of lipid-laden macrophages (LLMs) in bronchoalveolar lavage (BAL) fluid is useful for the diagnosis of pulmonary aspiration. To improve the diagnostic accuracy, an index was developed by assigning a score between zero and four to each macrophage depending on the amount of lipid in its cytoplasm and summing the scores of 100 consecutive macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A LLM index of &gt;100 is considered to be consistent with aspiration. A subsequent study suggested a LLM index of 165 as a threshold for detecting aspiration, because this value increases specificity with little effect on sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an increase in LLMs has been described in some pulmonary conditions other than aspiration, such as fat embolism secondary to trauma or sickle cell disease, infection (bacterial, viral and fungal), intravenous lipid infusion, and the use of certain drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In addition, some investigators have noted LLMs behind totally obstructed bronchi, where the possibility of aspiration is remote [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/29\">",
"     29",
"    </a>",
"    ]. These observations suggest that any pulmonary insult severe enough to cause tissue destruction may release lipids from cell membranes and surfactant, resulting in increased numbers of LLMs. Thus, the LLM index may be sensitive but not specific for pulmonary aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105455\">",
"    <span class=\"h2\">",
"     Novel methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of specific milk proteins in alveolar macrophages, recovered from BAL fluid and identified by immunocytochemistry, has been shown to be a more sensitive and specific marker for pulmonary aspiration in animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/33\">",
"     33",
"    </a>",
"    ]. In human infants, there was only a weak association between immunostaining results and measures of gastroesophageal reflux disease, suggesting that this technique is probably not sufficiently sensitive or specific to be clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367105463\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20542347\">",
"    <span class=\"h2\">",
"     Feeding decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swallowing dysfunction leading to aspiration presents major therapeutic challenges that often require the efforts of a coordinated multidisciplinary team consisting of the patient&rsquo;s primary caregiver, health care providers with expertise in swallowing (speech and occupational therapists), and selected pediatric subspecialists (pulmonologist, gastroenterologist, neurologist).",
"   </p>",
"   <p>",
"    The goals of therapy are safe and efficient feeding that preserves stable respiratory function and adequate nutrition. Oral feeding, while always desirable, is not always the goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/4,35,36\">",
"     4,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there are primary anatomical abnormalities that predispose to aspiration, these should be surgically corrected.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    or nasogastric tube feeding may be necessary to meet caloric requirements during the recovery period. The same methods for nutritional support should be considered when the patient&rsquo;s swallowing dysfunction is secondary to a transient disease such as myasthenia gravis.",
"   </p>",
"   <p>",
"    The treatment of swallowing dysfunction caused by functional abnormalities is more problematic. Changes in position and posture, modification of bolus size, and the alterations of consistency, shape, texture and temperature of food should be considered based on MBS study results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]. Although helpful in diagnosing swallowing dysfunction, MBS has low sensitivity for detecting pulmonary aspiration. Therefore, children with a negative MBS may still aspirate. Less frequently, the MBS may have false positive results, particularly in infants, who occasionally aspirate a small amount of food without developing clinically respiratory symptoms. Because of these limitations, neither the MBS nor any other test for aspiration can accurately predict clinically important aspiration, and management decisions must be individualized and informed by clinical risk factors and course. (See",
"    <a class=\"local\" href=\"#H367105407\">",
"     'Videofluoroscopic modified barium swallow'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20618761\">",
"    <span class=\"h2\">",
"     Gastrostomy placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with neurologic impairment, documentation of clear aspiration during a MBS study, and chronic pulmonary symptoms attributable to recurrent aspiration, we usually recommend placement of a gastrostomy tube or skin-level gastrostomy device (button) and cessation of oral feeding. Parents may initially be reluctant to have a gastrostomy placed because of concerns about losing pleasure of eating, or concerns about discomfort or cosmesis. The importance of preventing pulmonary aspiration, long-term benefits of improved nutrition, and reversibility of this procedure should be emphasized. In addition, a speech or occupational therapist should be consulted to provide oral-motor and swallow stimulation therapy. With treatment, swallowing function may improve in some patients and oral feeding may be restarted when deemed to be safe clinically. If the patient does well on oral feeds, the gastrostomy tube may be removed.",
"   </p>",
"   <p>",
"    General considerations about gastrostomy placement and enteral feeding are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27705093\">",
"    <span class=\"h2\">",
"     Salivary aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients receiving gastrostomy tube feedings exclusively, aspiration pneumonitis may persist as a result of the inability to swallow saliva and the pooling of secretions. Most of these patients have profound laryngeal incompetence and down-regulated cough owing to severe CNS dysfunction. Tastes of liquid or food may assist purposeful swallowing that reduces the risk of aspiration from pooled saliva. In addition, anticholinergic agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/9/34960?source=see_link\">",
"     scopolamine",
"    </a>",
"    patches, can be tried to inhibit salivation. In some individuals, surgical removal of salivary glands may have a beneficial effect. In rare instances, laryngotracheal separation with a permanent tracheostomy may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15962?source=see_link&amp;anchor=H25#H25\">",
"     \"Management and prognosis of cerebral palsy\", section on 'Drooling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20618754\">",
"    <span class=\"h2\">",
"     Fundoplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundoplication is most often considered in patients with severe neurologic impairment, who tend to have disordered gastrointestinal motility which predisposes to gastroesophageal reflux, as well as impaired airway protective mechanisms. There are risks and benefits to performing a fundoplication at the time of gastrostomy tube placement, and the decision should be based on consideration of an individual patient&rsquo;s characteristics: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fundoplication reduces gastroesophageal reflux and reduces the risk for aspiration of the refluxed gastric contents. This consideration is most important for patients with severe gastroesophageal reflux",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor gastric emptying.",
"     </li>",
"     <li>",
"      Fundoplication may exacerbate difficulties swallowing oral secretions, and may increase the risk of aspiration through this mechanism. This consideration is most relevant to patients with substantial neurological disease and difficulty handling oral secretions.",
"     </li>",
"     <li>",
"      Complications after fundoplication include recurrence of gastroesophageal reflux due to breakdown of the wrap, retching, esophageal obstruction, and intrathoracic herniation; complications are most common in patients with neurologic impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failure of initial surgery requiring re-operation ranges from 5 to 26 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To evaluate the potential risks and benefits of fundoplication prior to gastrostomy placement, we perform a gastric emptying scan and esophageal pH monitoring to assess for the frequency and severity of reflux. Most patients with mild reflux can be effectively managed without fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/9\">",
"     9",
"    </a>",
"    ]. Therefore, we suggest performing fundoplication only if there is evidence of severe gastroesophageal reflux, and if the airway protective mechanisms are thought to be inadequate. If the decision is unclear, it is reasonable to proceed with gastrostomy placement without fundoplication and to follow the patient clinically; fundoplication can be performed later if the patient has ongoing aspiration from refluxed food.",
"   </p>",
"   <p>",
"    In a retrospective cohort study of children with neurologic impairment, fundoplication reduced hospital admissions for gastroesophageal reflux disease and aspiration pneumonia, but not for asthma or non-aspiration pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16156267\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate strategy to reduce gastroesophageal reflux and the associated risks of aspiration is to place the feeding tube in the jejunum rather than in the stomach; this tends to reduce but not eliminate reflux. Disadvantages of jejunal feeds include a tendency for accidental displacement (except with permanent, surgically placed jejunal tubes) and intolerance of rapid feeding infusions. A retrospective study in a group of children with neurological impairment found that the rates of aspiration pneumonia and mortality were similar among those treated with jejunal feeding as compared to those treated with fundoplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, children with severe, irreversible neurological debilitation and intractable aspiration despite conventional therapy may require more aggressive surgical approaches such as tracheoesophageal diversion or laryngotracheal separation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38632/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/34/13858?source=see_link\">",
"       \"Patient information: Aspiration pneumonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16156477\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with swallowing dysfunction are at risk for pathologic aspiration. In these individuals, aspiration may result in acute or chronic pulmonary compromise, and impaired nutritional intake may lead to failure to thrive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomical abnormalities that predispose to aspiration include cleft",
"      <span class=\"nowrap\">",
"       lip/palate,",
"      </span>",
"      choanal atresia, micrognathia (eg, Pierre-Robin syndrome, craniofacial dysostosis), pharyngeal tumors and cysts, laryngeal cleft, tracheoesophageal fistula, and esophageal abnormalities (eg, vascular rings, strictures, achalasia). (See",
"      <a class=\"local\" href=\"#H367106155\">",
"       'Anatomic abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional disorders that predispose to aspiration include delayed maturation (eg, Down syndrome, prematurity), brain damage (eg, cerebral palsy, intrauterine infections, birth",
"      <span class=\"nowrap\">",
"       trauma/asphyxia,",
"      </span>",
"      intracranial hemorrhage,",
"      <span class=\"nowrap\">",
"       encephalitis/meningitis),",
"      </span>",
"      cranial nerve palsy (eg, poliomyelitis, meningitis, or central nervous system mass), and inherited diseases such as spinal muscular atrophy, familial dysautonomia, myotonic dystrophy, and myasthenia gravis. (See",
"      <a class=\"local\" href=\"#H367106162\">",
"       'Functional disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with swallowing dysfunction may display a weak suck, gagging, choking, disruptions in breathing, apnea, and cyanosis during feeding. Recurrent and chronic stridor may be present in some cases. Feeding difficulties may cause inadequate caloric intake and lead to failure to thrive. (See",
"      <a class=\"local\" href=\"#H367105391\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coughing during feeding is a prominent symptom in most children who aspirate food into the tracheobronchial tree, but may be absent in infants who aspirate or in children with chronic aspiration. (See",
"      <a class=\"local\" href=\"#H367105391\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The videofluoroscopic modified",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow (MBS), is the procedure of choice for evaluating the pharyngeal and esophageal phases of deglutition. It is generally performed after a clinical evaluation of swallowing by a speech-language pathologist, and the radiographic findings are interpreted in conjunction with the clinical findings. MBS has low sensitivity for detecting pulmonary aspiration, and false positives are occasionally seen, particularly in infants. (See",
"      <a class=\"local\" href=\"#H367105407\">",
"       'Videofluoroscopic modified barium swallow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quantification of the number of lipid-laden macrophages (LLM) in alveolar fluid obtained during bronchoalveolar lavage is sometimes used to evaluate a patient for chronic aspiration. However, an increase in LLMs has been described in some pulmonary conditions other than aspiration, so the test is probably sensitive but not specific for aspiration. (See",
"      <a class=\"local\" href=\"#H367105438\">",
"       'Lipid-laden macrophages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of patients with functional causes for swallowing dysfunction is complex, and depends on the degree to which swallowing mechanisms and airway protective mechanisms are impaired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with mild impairment can often be managed with changes in feeding position and posture, modification of bolus size, and the alterations of consistency, shape, texture, and temperature of food. These interventions are guided by MBS study results, in conjunction with clinical risk factors and course. (See",
"      <a class=\"local\" href=\"#H367105463\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with chronic neurologic impairment, documentation of clear aspiration during a MBS study, and chronic pulmonary symptoms attributable to recurrent aspiration, we recommend cessation of oral feeding and feeding through a gastrostomy or jejunal feeding device (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20618761\">",
"       'Gastrostomy placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not fed orally because of aspiration risk, and with well-documented severe gastroesophageal reflux or a clear history of recurrent reflux-induced aspiration, we suggest either fundoplication or jejunal feeding (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20618754\">",
"       'Fundoplication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16156267\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/1\">",
"      Darrow DH, Harley CM. Evaluation of swallowing disorders in children. Otolaryngol Clin North Am 1998; 31:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/2\">",
"      Derkay CS, Schechter GL. Anatomy and physiology of pediatric swallowing disorders. Otolaryngol Clin North Am 1998; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/3\">",
"      Garnett JD, Ramadan HH. Swallowing dysfunction after tonsillectomy. Otolaryngol Head Neck Surg 1996; 114:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/4\">",
"      Domenech E, Kelly J. Swallowing disorders. Med Clin North Am 1999; 83:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/5\">",
"      Shaker R, Milbrath M, Ren J, et al. Deglutitive aspiration in patients with tracheostomy: effect of tracheostomy on the duration of vocal cord closure. Gastroenterology 1995; 108:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/6\">",
"      Martin BJ, Corlew MM, Wood H, et al. The association of swallowing dysfunction and aspiration pneumonia. Dysphagia 1994; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/7\">",
"      Weir KA, McMahon S, Taylor S, Chang AB. Oropharyngeal aspiration and silent aspiration in children. Chest 2011; 140:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/8\">",
"      Thach BT. Maturation of cough and other reflexes that protect the fetal and neonatal airway. Pulm Pharmacol Ther 2007; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/9\">",
"      Boesch RP, Daines C, Willging JP, et al. Advances in the diagnosis and management of chronic pulmonary aspiration in children. Eur Respir J 2006; 28:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/10\">",
"      Morton RE, Bonas R, Fourie B, Minford J. Videofluoroscopy in the assessment of feeding disorders of children with neurological problems. Dev Med Child Neurol 1993; 35:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/11\">",
"      Wright RE, Wright FR, Carson CA. Videofluoroscopic assessment in children with severe cerebral palsy presenting with dysphagia. Pediatr Radiol 1996; 26:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/12\">",
"      Arvedson J, Rogers B, Buck G, et al. Silent aspiration prominent in children with dysphagia. Int J Pediatr Otorhinolaryngol 1994; 28:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/13\">",
"      Hiorns MP, Ryan MM. Current practice in paediatric videofluoroscopy. Pediatr Radiol 2006; 36:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/14\">",
"      Alnassar M, Oudjhane K, Davila J. Nasogastric tubes and videofluoroscopic swallowing studies in children. Pediatr Radiol 2011; 41:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/15\">",
"      Delzell PB, Kraus RA, Gaisie G, Lerner GE. Laryngeal penetration: a predictor of aspiration in infants? Pediatr Radiol 1999; 29:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/16\">",
"      Newman LA, Keckley C, Petersen MC, Hamner A. Swallowing function and medical diagnoses in infants suspected of Dysphagia. Pediatrics 2001; 108:E106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/17\">",
"      Friedman B, Frazier JB. Deep laryngeal penetration as a predictor of aspiration. Dysphagia 2000; 15:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/18\">",
"      da Silva AP, Lubianca Neto JF, Santoro PP. Comparison between videofluoroscopy and endoscopic evaluation of swallowing for the diagnosis of dysphagia in children. Otolaryngol Head Neck Surg 2010; 143:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/19\">",
"      McVeagh P, Howman-Giles R, Kemp A. Pulmonary aspiration studied by radionuclide milk scanning and barium swallow roentgenography. Am J Dis Child 1987; 141:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/20\">",
"      Baikie G, South MJ, Reddihough DS, et al. Agreement of aspiration tests using barium videofluoroscopy, salivagram, and milk scan in children with cerebral palsy. Dev Med Child Neurol 2005; 47:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/21\">",
"      Somasundaram VH, Subramanyam P, Palaniswamy S. Salivagram revisited: justifying its routine use for the evaluation of persistent/recurrent lower respiratory tract infections in developmentally normal children. Ann Nucl Med 2012; 26:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/22\">",
"      Drubach LA, Zurakowski D, Palmer EL 3rd, et al. Utility of salivagram in pulmonary aspiration in pediatric patients: comparison of salivagram and chest radiography. AJR Am J Roentgenol 2013; 200:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/23\">",
"      Corwin RW, Irwin RS. The lipid-laden alveolar macrophage as a marker of aspiration in parenchymal lung disease. Am Rev Respir Dis 1985; 132:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/24\">",
"      Colombo JL, Hallberg TK. Recurrent aspiration in children: lipid-laden alveolar macrophage quantitation. Pediatr Pulmonol 1987; 3:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/25\">",
"      Furuya ME, Moreno-C&oacute;rdova V, Ram&iacute;rez-Figueroa JL, et al. Cutoff value of lipid-laden alveolar macrophages for diagnosing aspiration in infants and children. Pediatr Pulmonol 2007; 42:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/26\">",
"      Stanley JD, Hanson RR, Hicklin GA, et al. Specificity of bronchoalveolar lavage for the diagnosis of fat embolism syndrome. Am Surg 1994; 60:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/27\">",
"      Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/28\">",
"      Recalde AL, Nickerson BG, Vegas M, et al. Lipid-laden macrophages in tracheal aspirates of newborn infants receiving intravenous lipid infusions: a cytologic study. Pediatr Pathol 1984; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/29\">",
"      Cohen AB, Cline MJ. In vitro studies of the foamy macrophage of postobstructive endogenous lipoid pneumonia in man. Am Rev Respir Dis 1972; 106:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/30\">",
"      Langston C, Pappin A. Lipid-laden alveolar macrophages as an indicator of aspiration pneumonia. Arch Pathol Lab Med 1996; 120:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/31\">",
"      Adams R, Ruffin R, Campbell D. The value of the lipid-laden macrophage index in the assessment of aspiration pneumonia. Aust N Z J Med 1997; 27:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/32\">",
"      Trinick R, Johnston N, Dalzell AM, McNamara PS. Reflux aspiration in children with neurodisability--a significant problem, but can we measure it? J Pediatr Surg 2012; 47:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/33\">",
"      Elidemir O, Fan LL, Colasurdo GN. A novel diagnostic method for pulmonary aspiration in a murine model. Immunocytochemical staining of milk proteins in alveolar macrophages. Am J Respir Crit Care Med 2000; 161:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/34\">",
"      De Baets F, Aarts C, Van Daele S, et al. Milk protein and Oil-Red-O staining of alveolar macrophages in chronic respiratory disease of infancy. Pediatr Pulmonol 2010; 45:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/35\">",
"      Arvedson JC. Management of pediatric dysphagia. Otolaryngol Clin North Am 1998; 31:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/36\">",
"      Wisdom G, Blitzer A. Surgical therapy for swallowing disorders. Otolaryngol Clin North Am 1998; 31:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/37\">",
"      Gisel EG, Applegate-Ferrante T, Benson J, Bosma JF. Oral-motor skills following sensorimotor therapy in two groups of moderately dysphagic children with cerebral palsy: aspiration vs nonaspiration. Dysphagia 1996; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/38\">",
"      Mathei J, Coosemans W, Nafteux P, et al. Laparoscopic Nissen fundoplication in infants and children: analysis of 106 consecutive patients with special emphasis in neurologically impaired vs. neurologically normal patients. Surg Endosc 2008; 22:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/39\">",
"      Kane TD, Brown MF, Chen MK, Members of the APSA New Technology Committee. Position paper on laparoscopic antireflux operations in infants and children for gastroesophageal reflux disease. American Pediatric Surgery Association. J Pediatr Surg 2009; 44:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/40\">",
"      Pacilli M, Chowdhury MM, Pierro A. The surgical treatment of gastro-esophageal reflux in neonates and infants. Semin Pediatr Surg 2005; 14:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/41\">",
"      Srivastava R, Berry JG, Hall M, et al. Reflux related hospital admissions after fundoplication in children with neurological impairment: retrospective cohort study. BMJ 2009; 339:b4411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/42\">",
"      Srivastava R, Downey EC, O'Gorman M, et al. Impact of fundoplication versus gastrojejunal feeding tubes on mortality and in preventing aspiration pneumonia in young children with neurologic impairment who have gastroesophageal reflux disease. Pediatrics 2009; 123:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38632/abstract/43\">",
"      Eibling DE, Snyderman CH, Eibling C. Laryngotracheal separation for intractable aspiration: a retrospective review of 34 patients. Laryngoscope 1995; 105:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14537 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38632=[""].join("\n");
var outline_f37_46_38632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16156477\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105855\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105375\">",
"      DEVELOPMENT OF FEEDING AND SWALLOWING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105383\">",
"      CAUSES OF SWALLOWING DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367106155\">",
"      Anatomic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367106162\">",
"      Functional disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367106177\">",
"      Iatrogenic causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105391\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105399\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367105407\">",
"      Videofluoroscopic modified barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367105422\">",
"      Fiberoptic endoscopic examination of swallowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367105430\">",
"      Gastroesophageal scintigraphy and salivagram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367105438\">",
"      Lipid-laden macrophages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367105455\">",
"      Novel methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367105463\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20542347\">",
"      Feeding decisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20618761\">",
"      Gastrostomy placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27705093\">",
"      Salivary aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20618754\">",
"      Fundoplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16156267\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16156477\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14537|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/16/4358\" title=\"figure 1\">",
"      Anatomy of pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14537|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/28/36299\" title=\"table 1\">",
"      Abnormal findings on a modified barium swallow",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40569?source=related_link\">",
"      Evaluation of dysphagia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=related_link\">",
"      Facial clefts and holoprosencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/34/13858?source=related_link\">",
"      Patient information: Aspiration pneumonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38633="Pharmacologic management of pain during labor and delivery";
var content_f37_46_38633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic management of pain during labor and delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Gilbert J Grant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/46/38633/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/46/38633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The way pain is experienced is a reflection of the individual's emotional, motivational, cognitive, social, and cultural circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/1\">",
"     1",
"    </a>",
"    ]. The pain of childbirth is likely to be the most severe pain that a woman experiences during her lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/2\">",
"     2",
"    </a>",
"    ]. Many women, especially nulliparas, rate the pain of labor as very severe or intolerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The pain of labor and delivery varies among women, and each labor of an individual woman may be quite different. As an example, an abnormal fetal presentation (eg, occiput posterior) is associated with more severe pain and may be present in one pregnancy, but not the next.",
"   </p>",
"   <p>",
"    Pharmacological treatment of labor pain was introduced in the mid-nineteenth century. These analgesic techniques were controversial, as many women and their physicians strongly believed that labor pain was a natural and necessary accompaniment of childbirth. This battle continues to the present day, with a vocal minority arguing that the use of pharmacological analgesic agents in parturients is unnecessary, unnatural, and harmful. Thus, laboring women are often treated differently than other patients suffering from pain. The American College of Obstetricians and Gynecologists (ACOG) has recognized this double-standard, noting that there is no other circumstance in which it is considered acceptable to experience severe pain, amenable to safe relief, while under a physician's care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. ACOG supports the concept that maternal request alone is a sufficient medical indication for labor analgesia.",
"   </p>",
"   <p>",
"    Although lower levels of labor pain have been correlated with higher levels of childbirth satisfaction, higher levels of labor pain do not preclude an overall satisfying experience. When interviewed after delivery, mothers tend to downplay the intensity of their labor pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/7\">",
"     7",
"    </a>",
"    ] and it is not the most important factor influencing satisfaction with the childbirth experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/8\">",
"     8",
"    </a>",
"    ]. However, a sense of personal control over decision-making processes in labor has consistently been shown to correlate with overall maternal satisfaction with childbirth. As an example, a study of 60 women who delivered vaginally found that personal control predicted greater maternal satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/9\">",
"     9",
"    </a>",
"    ]. Another study of 100 women undergoing vaginal delivery reported that satisfaction with pain relief was associated with a feeling of being in control and having input in the decision making process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that women should be involved in the decision-making process regarding all aspects of childbirth, including pain relief, to increase maternal satisfaction. This can be accomplished by educating women about pain relief techniques during pregnancy, prior to the onset of labor, so that women can carefully contemplate their options before labor commences, as rational decision-making is difficult during times of emotional stress and physical anguish. Furthermore, patient-controlled epidural analgesia (PCEA) empowers the parturient by giving her direct control of her pain relief, and this has the potential to increase maternal satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to labor pain and pharmacologic modalities for pain relief will be reviewed here. Specific issues regarding administration and complications of neuraxial anesthesia and nonpharmacologic approaches to manage labor pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/44/38601?source=see_link\">",
"     \"Nonpharmacological approaches to management of labor pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PAIN PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain originates from different sites as the process of labor and delivery progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     First stage of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain at this time occurs during contractions, is visceral or cramp-like in nature, originates in the uterus and cervix, and is produced by distention of uterine and cervical mechanoreceptors and by ischemia of uterine and cervical tissues. The pain signal enters the spinal cord after traversing the T10, T11, T12, and L1 white rami communicantes. In addition to the uterus, labor pain can be referred to the abdominal wall, lumbosacral region, iliac crests, gluteal areas, and thighs.",
"   </p>",
"   <p>",
"    Transition refers to the shift from the late first stage (7 to 10 cm cervical dilation) to the second stage of labor. Transition is associated with greater nociceptive input as the parturient begins to experience somatic pain from vaginal distention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Second stage of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic pain from distention of the vagina, perineum, and pelvic floor and stretching of the pelvic ligaments is the hallmark of the second stage of labor. The pain signal is transmitted to the spinal cord via three sacral nerves (S2, S3, and S4), which comprise the pudendal nerve. Second stage pain is more severe than first stage pain and is characterized by a combination of visceral pain from uterine contractions and cervical stretching and somatic pain from distention of vaginal and perineal tissues. In addition, the parturient experiences rectal pressure and an urge to \"bear down\" and expel the fetus as the presenting part descends into the pelvic outlet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ADVERSE CONSEQUENCES OF LABOR PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of labor produces physiological changes in addition to emotional distress and suffering (",
"    <a class=\"graphic graphic_table graphicRef55211 \" href=\"mobipreview.htm?7/20/7499\">",
"     table 1",
"    </a>",
"    ). These changes have an impact on many maternal systems, and also affect the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperventilation consistently accompanies labor pain. Arterial CO2 partial pressures less than 20 mmHg are not uncommon, and profound hypocarbia may inhibit ventilatory drive between contractions and result in maternal hypoxemia, lightheadedness, and loss of consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/15\">",
"     15",
"    </a>",
"    ]. Respiratory alkalosis, which impairs placental oxygen transfer from the maternal to fetal circulation, may occur. Alkalosis shifts the oxyhemoglobin dissociation curve to the left, increasing the affinity of oxygen for maternal hemoglobin, thereby decreasing off-loading of oxygen to the fetus. Maternal alkalosis can also impair fetal oxygen availability via utero-placental vasoconstriction, which decreases uterine blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/16\">",
"     16",
"    </a>",
"    ]. These changes are usually well-tolerated in healthy parturients with normal pregnancies.",
"   </p>",
"   <p>",
"    Maternal transcutaneous PO2 as low as 44 mmHg has been observed during contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/17\">",
"     17",
"    </a>",
"    ]. Epidural analgesia reverses the adverse ventilatory effects of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/18\">",
"     18",
"    </a>",
"    ] and results in an increase in oxygen tension in both mother and fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/19\">",
"     19",
"    </a>",
"    ], which may be beneficial, especially when additional conditions contributing to fetal or maternal hypoxemia are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurohumoral effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurohumoral responses to stress and pain may adversely affect placental perfusion and fetal oxygenation. Studies in sheep demonstrated that pain increased circulating catecholamines and significantly decreased blood flow to the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/20\">",
"     20",
"    </a>",
"    ]. In pregnant primates, stress and pain were shown to lower fetal oxygenation, cause fetal acidosis, and slow fetal heart rate. These changes may be of clinical concern when other conditions contributing to fetal hypoxemia are also present.",
"   </p>",
"   <p>",
"    Removal of the stressful stimulus or sedation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    reversed these changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/21\">",
"     21",
"    </a>",
"    ]. The adverse effect of elevated circulating levels of epinephrine induced by maternal agitation and anxiety on fetal heart rate has also been documented in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/22\">",
"     22",
"    </a>",
"    ]. Epidural analgesia results in decreased concentrations of circulating maternal epinephrine, probably by reducing maternal pain and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/23\">",
"     23",
"    </a>",
"    ]. Epidural analgesia also results in a reduction of plasma beta-endorphin and cortisol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Psychological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to untoward physiological effects, unrelieved pain may also be a factor that contributes to the development of postpartum psychological trauma. Women who experience unrelieved pain during childbirth may be more likely to develop postpartum depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/25\">",
"     25",
"    </a>",
"    ]. In a study of 1288 women following vaginal or cesarean delivery, the severity of acute postpartum pain, rather than the mode of delivery, correlated with the incidence of postpartum depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/26\">",
"     26",
"    </a>",
"    ]. A more severe form of postpartum psychological trauma is posttraumatic stress disorder (PTSD). The prevalence of PTSD after childbirth has been reported to range from 1.7 to 6.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/27\">",
"     27",
"    </a>",
"    ]. A larger percentage of postpartum women develop some posttraumatic stress symptoms, but not the full-blown disorder. Although the etiology of PTSD is complex and multifactorial, unrelieved pain during childbirth has been identified as a risk factor for its development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/28\">",
"     28",
"    </a>",
"    ]. The profoundly harmful effects of postpartum PTSD on new mothers should not be underestimated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANALGESIA FOR THE FIRST STAGE OF LABOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic approaches to manage childbirth pain can be broadly classified as either systemic or locoregional. Systemic administration includes the intravenous, intramuscular, and inhalation routes. Regional techniques (neuraxial) consist of epidurals, spinals and combined spinal-epidurals, and are the most popular modalities for analgesia for childbirth. Neuraxial techniques are widely acknowledged to be the only consistently effective means of relieving the pain of labor and delivery. Local injection may also be administered to achieve paracervical or pudendal nerve block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic analgesics are useful for patients who prefer less invasive techniques, or in whom regional techniques are contraindicated, or are not an option due to lack of availability of skilled providers. The most popular systemic agents are opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    ) or mixed opioid agonists-antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    ). Opioids exert their effects in the maternal brain, although a portion of the dose also crosses the placenta and affects the fetus. This is manifested in utero by decreased fetal heart rate variability and in the neonate by respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although systemic analgesics provide an alternative to regional analgesia, they are not as effective and produce respiratory depression. In laboring women, systemic opioids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    produce relief by inducing somnolence rather than by producing analgesia per se [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/32\">",
"     32",
"    </a>",
"    ]. In a study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and meperidine, repeated intravenous administration resulted in increasing sedation scores in parturients with little change in pain scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A list of systemic analgesics used in labor and delivery is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef55888 \" href=\"mobipreview.htm?36/25/37277\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A systematic review of randomized trials of parenteral opioids for labor pain relief noted considerable heterogeneity among studies and many limitations to data interpretation (eg, low power, methodology issues) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/34\">",
"     34",
"    </a>",
"    ]. The major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Satisfaction with pain relief provided by opioids during labor was low and only slightly better than placebo (29 versus 17 percent, p = 0.04). There was no evidence that any opioid was significantly more effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      , which is widely available and inexpensive. However, side effect profiles differed.",
"     </li>",
"     <li>",
"      Epidural analgesia provided better pain relief than parenteral opioids. However, opioids were associated with a shorter duration of labor and less",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation. Although opioids were also associated with fewer instrumental deliveries compared to epidural analgesia, only two trials evaluated this outcome. Furthermore, higher concentrations of local anesthetics, relative to current mixtures, were utilized in these trials.",
"     </li>",
"     <li>",
"      Nausea, vomiting, and sedation were common maternal side effects. Respiratory depression was the major neonatal concern; further investigation is required regarding possible long-term effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High doses of opioids are usually needed to obtain good pain relief; however, at these dosages maternal aspiration and maternal and neonatal respiratory depression are significant concerns. Parenteral opioids decrease fetal heart rate variability; therefore, consideration of alternative analgesic methods is useful when the fetus is at high risk for or demonstrates a nonreassuring fetal heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Classic opioid analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly prescribed systemic opioid for labor pain relief worldwide is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , a synthetic opioid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/34\">",
"     34",
"    </a>",
"    ]. However, its use has fallen into disfavor in the United States and there is a movement to replace meperidine with more efficacious and less toxic opioid analgesics because of its potential side effects (eg, serotonergic crisis, seizures and normeperidine toxicity) and multiple drug interactions (eg, MAO inhibitors).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is a less popular choice, but is occasionally used to provide labor analgesia. However, the lack of efficacy of these medications and their associated maternal and neonatal side effects have resulted in decreased usage in many labor units where superior means of analgesia, such as regional techniques, are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/33,36\">",
"     33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    reaches a maximal concentration in the fetus between two and three hours after maternal dosing. As a result, classic teaching became that the neonate should be delivered within one hour or greater than four hours after a meperidine dose. Timing of delivery, however, is difficult to predict with precision. In addition, the metabolite normeperidine has pharmacologic activity and a prolonged half-life in the neonate (2.5 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/37\">",
"     37",
"    </a>",
"    ], thus it may affect neonatal behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/38\">",
"     38",
"    </a>",
"    ] and difficulty with breastfeeding regardless of the timing of maternal administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Newer opioid analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    , a synthetic opioid, and its congeners (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    ) have also been used to provide labor pain relief. These drugs have a short duration of action, so they are best administered using the intravenous, rather than the intramuscular route. Of these agents, only fentanyl and remifentanil are suited for systemic labor analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically, the opioid best suited for providing labor analgesia using a systemic approach is a drug such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    , which is metabolized by nonspecific plasma and tissue esterases. Remifentanil rapidly transfers across the placenta, but is metabolized rapidly in the fetus and thus should not produce neonatal depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/41\">",
"     41",
"    </a>",
"    ]. Its rapid onset of action, within one minute following intravenous injection, is another advantage for the parturient. For these reasons, remifentanil is gaining popularity for providing analgesia for childbirth in parturients in whom regional analgesia is either contraindicated or not desired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/40,42-44\">",
"     40,42-44",
"    </a>",
"    ], but further studies are needed to refine the methodology for its safe administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Opioids with mixed agonist-antagonist properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed opioid agonist-antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    ) for pain relief have the advantage of a dose ceiling effect with regard to respiratory depression. Butorphanol, for example, at doses greater than 10 mg intensifies analgesia without producing greater respiratory depression. These agents are associated with opioid side effects in the mother and fetus; psychotomimetic effects are particularly disconcerting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Patient controlled analgesia (PCA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of intravenous PCA does not match that of regional analgesia, PCA is an appropriate choice for the parturient in whom neuraxial analgesia is contraindicated, or if the woman refuses neuraxial instrumentation.",
"   </p>",
"   <p>",
"    PCA provides rapid onset of analgesia, fine control of pain relative to side effects, and psychological independence for the patient.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a familiar opioid and a popular choice, with a typical regimen being a 50 to 100 mcg loading dose and a patient-controlled dose of 20 to 60 mcg every 5 to 10 minutes.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     Remifentanil",
"    </a>",
"    , due to its rapid onset and rapid metabolism, is increasingly being used to provide labor analgesia.",
"   </p>",
"   <p>",
"    Various intravenous PCA regimens for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    have been reported to provide analgesia during labor, with basal infusions ranging from 0 to 0.05",
"    <span class=\"nowrap\">",
"     mcg/kg/min,",
"    </span>",
"    bolus doses of 25 to 50 mcg, and lockout times of one to five minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/40\">",
"     40",
"    </a>",
"    ]. Although some data indicate that remifentanil is generally well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/46\">",
"     46",
"    </a>",
"    ], it is prudent to monitor the parturient and her neonate for hypoxemia when intravenous PCA remifentanil is used since the drug is a potent respiratory depressant that may produce sedation and hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A practical problem of using remifentanil is that very brief lockout intervals (one to five minutes) are required, a shorter interval than is permitted by some standard PCA pumps. If any intravenous opioid is administered, maternal respiration must be continually monitored, because these agents are potent respiratory depressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nonopioid agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used non-opioid agents are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    , a phenothiazine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , an antihistamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/49\">",
"     49",
"    </a>",
"    ]. These drugs are often administered in combination with an opioid to potentiate analgesia and decrease side effects, such as nausea and vomiting. They are less effective used alone than opioids, although they appear to provide some relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barbiturates such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/27/32182?source=see_link\">",
"     secobarbital",
"    </a>",
"    are hypnotics and anxiolytics, not analgesics. They may be administered orally and are sometimes prescribed by obstetricians to enable a patient to sleep through early labor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    is a muscarinic anticholinergic drug that induces a dissociative state. Scopolamine was used in combination with an opioid for \"twilight sleep,\" a technique popularized at the beginning of the 20th century, but it causes delirium and extreme agitation, sedation, and amnesia, and is rarely used for labor analgesia today.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a phencyclidine derivative that produces a dissociative state and analgesia. It is a potent amnestic, and has a rapid onset of action (less than one minute after intravenous administration). Ketamine tends to preserve airway reflexes, but also increases airway secretions, which may lead to laryngospasm. Its propensity to produce psychotomimetic effects may be prevented with coadministration of benzodiazepines. Ketamine will induce general anesthesia at doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    but lower doses may be used to provide analgesia for vaginal delivery or minor operative procedures, such as manual uterine exploration. Doses above 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may cause uterine hypertonicity and decrease uteroplacental perfusion.",
"   </p>",
"   <p>",
"    Benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ) are anxiolytics that may be used for sedation during vaginal delivery. Midazolam is preferred because it is nonirritating to veins, and has a short duration of action. Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , benzodiazepines are potent amnestics that may impair the mother's memory of the birth if administered during labor. In addition, airway reflexes are obtunded, which is a risk factor for aspiration, especially since parturients in labor typically have increased gastric contents and delayed gastric emptying. Ketamine and benzodiazepines undergo placental passage and may result in neonatal depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nitrous oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    inhalation analgesia (usually a blend of 50% nitric oxide and 50% oxygen gas) for labor pain has been commonly used for decades in Great Britain, Scandinavia, Australia, Canada, and other countries, but rarely in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The parturient self-administers the anesthetic gas, as needed, using a hand-held face mask. Correctly timing each inhalation is important because analgesia takes up to 50 seconds to take effect, thus peak analgesia will occur out of phase with uterine contractions if the gas is administered with onset of contractions, which usually peak 30 seconds after they begin and last one minute.",
"   </p>",
"   <p>",
"    Due to the time lag for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    to take effect, inhalation should begin approximately 30 seconds before the contraction is expected to begin and should cease as the contraction begins to recede. This makes use of nitrous oxide particularly challenging during the second stage, as the parturient needs to be alert to push during the contraction.",
"   </p>",
"   <p>",
"    The safety of this technique is that the parturient will be unable to hold the mask if she becomes too drowsy, and thus will cease to inhale the anesthetic. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    is eliminated quickly via the lungs, it does not accumulate in the mother or",
"    <span class=\"nowrap\">",
"     fetus/neonate",
"    </span>",
"    or cause newborn depression, and is thought to be generally safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. An additional advantage is that it does not affect contractile activity. However, pulse oximetry and gas scavenging systems are essential during its use; even so, environmental pollution is common. Also, it is known that exposure to anesthetics and sedatives causes neurodegeneration in developing animals, and although this link has not been established in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/54\">",
"     54",
"    </a>",
"    ], some investigators advocate avoidance of inhalation agents in pregnant women and infants, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The analgesic efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    for labor is unclear. Systematic reviews have found that it relieves labor pain to a significant degree in most patients, but does not provide complete analgesia for many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/53,56-58\">",
"     53,56-58",
"    </a>",
"    ]. However, few fair or good quality studies were available and they did not provide clear, quantitative, objective evidence of its analgesic efficacy for the relief of labor pain. Nevertheless, for women who choose to avoid neuraxial analgesia or for those who do not have access to it, nitrous oxide may provide an alternative means to achieve some pain relief.",
"   </p>",
"   <p>",
"    The American Society of Anesthesiologists (ASA) Committee on Obstetrical Anesthesia recommends that health care facilities have written protocols for use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    and that nursing and obstetric providers be educated on its safe use, with periodic assessment of competence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/59\">",
"     59",
"    </a>",
"    ]. Use of inhaled nitrous oxide for labor analgesia should conform to sedation policies established by the institution&rsquo;s Department of Anesthesiology. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Local injection techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of the first and second stages of labor may be ameliorated by injection of anesthetics locally. The obstetrical provider usually performs these injections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neuraxial analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial techniques provide unparalleled pain relief for labor and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/49\">",
"     49",
"    </a>",
"    ]. In the United States, spinals and epidurals are used by more than 70 percent of women who give birth in hospitals with greater than 1500 deliveries per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/60\">",
"     60",
"    </a>",
"    ]. Medical indications for neuraxial analgesia include anticipated difficulty with intubation, history of malignant hyperthermia, some cardiovascular and respiratory disorders, and prevention of autonomic hyperreflexia in women with a high spinal cord lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/5\">",
"     5",
"    </a>",
"    ]. Neuraxial anesthesia is preferred for women with preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absolute contraindications to neuraxial analgesia include patient refusal, uncorrected coagulopathy (due to risk of",
"    <span class=\"nowrap\">",
"     spinal/epidural",
"    </span>",
"    hematoma), infection of the lower back (due to risk of seeding of the neuraxis with bacteria), uncorrected hypovolemia (due to risk of profound hypotension from sympathetic block), and increased intracranial pressure (due to risk of herniation of the cerebral contents through the foramen magnum if dural puncture were to occur).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Epidural techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetics, such as 0.03 to 0.125 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    or 0.075 to 0.2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    , administered via the epidural route using continuous infusion pumps, provide safe and effective labor analgesia. The higher concentrations (eg, 0.125 percent bupivacaine or 0.2 percent ropivacaine) may be used alone, but for lower concentrations of local anesthetics to be effective (eg, as part of an \"ultra-low dose\" technique), they must be combined with other analgesics, most commonly neuraxial opioids. Neuraxial opioids alone, whether delivered by the intrathecal or epidural route, also provide excellent analgesia for the early first stage of labor. However, opioids alone do not reliably block the somatic pain component of late first stage (transition) or second stage of labor. A popular approach is to administer a combination of local anesthetic and opioid by continuous epidural infusion throughout labor. Most anesthesiologists use relatively lipid soluble synthetic opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ) to reduce the high incidence of side effects seen with epidural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . Typical formulations for continuous epidural analgesia are bupivacaine 0.04 to 0.125 percent or ropivacaine 0.1 to 0.2 percent combined with fentanyl 0.5 to 3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or sufentanil 0.25 to 1",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Some",
"    practitioners add epinephrine to the mix. Epinephrine enhances analgesia by activating neuraxial alpha-2 receptors, thus permitting a reduction in the concentration of local anesthetic administered. This reduction offsets an undesirable effect of epinephrine, namely its tendency to intensify local anesthetic-induced motor block. A benefit of adding epinephrine is that it may help to identify an unintentional intravascular injection, increasing maternal heart rate through its beta-1 agonist effects. Some practitioners use a small volume of concentrated local anesthetic containing epinephrine as a test dose after inserting the epidural catheter (eg, 3 mL",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    1.5 percent with 1:200,000 epinephrine) to rule out intravascular or intrathecal placement. Others forego the test dose because \"ultra-low dose\" analgesic formulations are unlikely to result in toxicity, even if accidentally injected intravascularly or intrathecally. Also, administration of a relatively high concentration of local anesthetic in the test dose is likely to produce unwanted motor block, and unintended intravascular injection of the epinephrine component may decrease placental blood flow due to alpha adrenergic mediated uterine arterial constriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moreover, wide fluctuations in maternal heart rate that occur during labor may mask epinephrine-induced increases in heart rate. Use of a baseline-to-peak increase greater than 10",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    has been shown to eliminate this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .) Infusion pumps are commonly used to facilitate continuous epidural drug administration. A typical regimen includes a loading dose of 10 to 20 mL, followed by an hourly infusion of 5 to 10 mL. If patient-controlled epidural analgesia (PCEA) is also used, patients may then self-administer doses at set intervals (eg, 3 to 10 mL every 10 to 30 minutes).",
"   </p>",
"   <p>",
"    Breakthrough pain that occurs during continuous epidural infusion may be managed by administering a bolus dose of the infusate, and perhaps by increasing the basal rate of the infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by administration of a more concentrated dose of anesthetic as a \"rescue dose,\" such as 3 to 6 mL of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    every 15 minutes as needed until the parturient is comfortable.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"     Ropivacaine",
"    </a>",
"    0.2 percent may be used instead of bupivacaine in this situation, but concentrated doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (eg, 1.5 to 2 percent) are best avoided, as they tend to cause a more intense motor block than do bupivacaine or ropivacaine.",
"   </p>",
"   <p>",
"    With epidural techniques, \"ultra-low dose\" concentrations of local anesthetics may not be adequate to relieve the intense pain of the second stage of labor, as local anesthetic requirements increase as labor progresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/63\">",
"     63",
"    </a>",
"    ]. For parturients who have epidural analgesia initiated late in labor (ie, during the late first stage [\"transition\"] or during the second stage), a higher concentration anesthetic (eg, 3 to 6 mL 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) should be added to the initial 10 to 20 mL loading dose of \"ultra-low dose\" local anesthetic. Additional 3 to 6 mL doses of 0.25 percent bupivacaine may be administered as needed if pain persists after 15 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Spinal techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal or combined spinal-epidural (CSE) techniques may also be used to relieve labor pain. Intrathecal analgesia with opioid alone (eg, 5 to 10 mcg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    or 10 to 20 mcg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) during very early labor permits ambulation because spinal opioids have no effect on muscle strength. The intrathecal approach is also useful for the painful contractions of late first stage (\"transition\") because onset of analgesia is faster than with the epidural approach. Analgesia for the relatively severe pain of transition may be more reliably achieved by combining a small dose of local anesthetic (eg, 2 to 2.5 mg isobaric",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    with an opioid, eg, 5 to 10 mcg sufentanil or 10 to 20 mcg fentanyl).",
"   </p>",
"   <p>",
"    Compared to epidural techniques, spinal techniques have a more rapid onset: the patient is typically comfortable within five minutes. However, the pain relief is relatively short-lived, approximately 90 minutes. This is because catheters for administering additional doses of analgesics are usually not inserted into the intrathecal space. Therefore, if delivery is not imminent, a CSE technique is preferred.",
"   </p>",
"   <p>",
"    The advantage of the CSE technique is that the epidural catheter may be activated if delivery has not occurred before the intrathecal dose wears off, if the spinal medication does not produce adequate analgesia, or if an instrumental or operative delivery is required. Most practitioners start the epidural infusion immediately following the CSE because it has been demonstrated that this approach produces longer analgesia compared to starting the infusion at the time of patient request [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/64\">",
"     64",
"    </a>",
"    ]. On the other hand, compared to low-dose epidural techniques, spinal administration of opioids is associated with a greater incidence of fetal bradycardia and pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/65\">",
"     65",
"    </a>",
"    ]. The fetal bradycardia is associated with uterine hypertonus, and is postulated to be due to a transient catecholamine imbalance. This imbalance involves an acute decrease in epinephrine levels with loss of epinephrine's tocolytic effect, and a relative increase in the uterotonic effect of norepinephrine. Catecholamine imbalance is not as likely to occur with epidural analgesia, which has a slower onset of action than spinal analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal administration of local anesthetics may also induce maternal hypotension due to sympathectomy, but lower doses of local anesthetics should reduce this likelihood. However, maternal hypotension may also occur after administration of intrathecal opioids alone, presumably due to rapid onset of pain relief, and an acute decrease in circulating catecholamine levels, as intrathecal opioid administration (with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    ) does not produce a sympathectomy per se [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ANALGESIA/ANESTHESIA FOR THE SECOND STAGE OF LABOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Continuation of epidural infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a continuous epidural technique or patient controlled epidural analgesia (PCEA) is used for the first stage of labor, the volume of infusate is often sufficient to produce the sacral analgesia needed for the second stage.",
"   </p>",
"   <p>",
"    Ideally, the parturient maintains motor strength and senses pressure during the second stage, and the epidural infusion is continued to provide analgesia through delivery. However, if motor block is too intense and if a pressure sensation is not appreciated, the infusion may need to be stopped temporarily or decreased and the motor block allowed to dissipate. If this is done, the parturient should be encouraged to begin pushing as the effect wanes, but before the pain returns.",
"   </p>",
"   <p>",
"    Some obstetricians prefer to discontinue epidural analgesia late in labor in the hope of decreasing the likelihood of instrumental delivery. A systematic review of this subject found insufficient evidence to support this practice, but did show that discontinuing epidural analgesia increases the rate of inadequate pain relief in the second stage of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link&amp;anchor=H12560419#H12560419\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Potential benefits of delayed pushing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initiation of analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are situations in which neuraxial analgesia is not initiated until the second stage of labor. The parturient may not have desired neuraxial block earlier in labor or the fetal heart rate tracing or position may necessitate an instrumental delivery (eg, forceps or vacuum). Initiation of epidural analgesia is possible at this juncture, but the prolonged latency may make this choice less desirable than a spinal technique. Contraindications are the same as those listed above (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Neuraxial analgesia'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    If an epidural is used, ultra-low concentrations of local anesthetics will likely be insufficient to relieve the intense pain of the second stage. We empirically add 3 mL 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    to the standard high volume (20 mL) low-concentration formulation of",
"    <span class=\"nowrap\">",
"     bupivacaine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"      sufentanil",
"     </a>",
"     /epinephrine",
"    </span>",
"    administered; additional 3 mL doses are given if pain persists after 15 minutes. Another reasonable option for providing second stage analgesia is to perform a spinal or CSE using a local anesthetic-opioid combination (eg, 2 mg isobaric bupivacaine and 5 mcg sufentanil given intrathecally). This has a rapid onset: the patient is typically comfortable within five minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pudendal nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral pudendal nerve blocks are useful for alleviating pain arising from vaginal and perineal distention during the second stage of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/49\">",
"     49",
"    </a>",
"    ]. They may be used as a supplement for epidural analgesia if the sacral nerves are not sufficiently anesthetized. Pudendal nerve blocks may also be performed to provide analgesia for low forceps, but they are inadequate for mid-forceps delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anesthesia for urgent situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric complications occurring during the second stage of labor (eg, shoulder dystocia or entrapment of the fetal head with breech presentations) may require urgent anesthetic intervention. If a working epidural or spinal is not in place, it may be necessary to induce general anesthesia. A rapid sequence induction is indicated due to the \"full stomach\" status of parturients. The trachea is quickly intubated with a cuffed endotracheal tube to protect the lungs from aspiration of gastric contents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction of general anesthesia and inhalation of a high concentration of volatile anesthetic will produce rapid uterine relaxation, facilitating delivery of an entrapped fetal head. However, if the parturient has a functioning regional anesthetic, intravenous administration of a low dose of the smooth muscle relaxant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (eg, 50 mcg) may be used to produce uterine relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/46/38633/abstract/69\">",
"     69",
"    </a>",
"    ] and facilitate delivery without exposing the parturient to the risks of induction of general anesthesia. Hypotension resulting from the nitroglycerin may be treated with small doses of ephedrine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    . Intravenous nitroglycerin is also indicated for other situations in which uterine relaxation is desirable without the need for general anesthesia, such as retained placenta or uterine inversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       \"Patient information: Labor and delivery (childbirth) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=see_link\">",
"       \"Patient information: Managing pain during labor and delivery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a variety of pharmacological options to manage the pain of parturition. Opioids administered systemically act primarily by inducing somnolence, rather than by producing analgesia per se. Moreover, placental transfer of opioids to the fetus may produce neonatal respiratory depression. If systemic opioids are used, they are optimally delivered with an intravenous patient-controlled analgesia (PCA) regimen. Systemic opioids may be the only option in settings with limited resources, or if regional analgesia (epidural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spinal) is contraindicated.",
"     </li>",
"     <li>",
"      Regional analgesic techniques, epidurals, spinals, and combined spinal-epidurals (CSE) are the most reliable means of relieving the pain of labor and delivery. By blocking the maternal stress response, epidural and spinal analgesia may reverse the untoward physiological consequences of labor pain. A distinct advantage of inserting an epidural catheter is that it may be used to administer anesthetics to provide pain relief for instrumental or cesarean delivery, if required. We recommend use of regional analgesia to manage the pain of labor and delivery for parturients desiring pharmacologic analgesia, in the absence of a contraindication. Furthermore, unless delivery is imminent, we recommend that an epidural catheter be inserted as a component of the regional technique.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/1\">",
"      Lowe NK. The nature of labor pain. Am J Obstet Gynecol 2002; 186:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/2\">",
"      Melzack R. The myth of painless childbirth (the John J. Bonica lecture). Pain 1984; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/3\">",
"      Ranta P, Spalding M, Kangas-Saarela T, et al. Maternal expectations and experiences of labour pain--options of 1091 Finnish parturients. Acta Anaesthesiol Scand 1995; 39:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/4\">",
"      Melzack R, Taenzer P, Feldman P, Kinch RA. Labour is still painful after prepared childbirth training. Can Med Assoc J 1981; 125:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/5\">",
"      Goetzl LM, ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric analgesia and anesthesia. Obstet Gynecol 2002; 100:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/6\">",
"      ACOG Committee Opinion #295: pain relief during labor. Obstet Gynecol 2004; 104:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/7\">",
"      Waldenstr&ouml;m U. Women's memory of childbirth at two months and one year after the birth. Birth 2003; 30:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/8\">",
"      Hodnett ED. Pain and women's satisfaction with the experience of childbirth: a systematic review. Am J Obstet Gynecol 2002; 186:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/9\">",
"      Goodman P, Mackey MC, Tavakoli AS. Factors related to childbirth satisfaction. J Adv Nurs 2004; 46:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/10\">",
"      McCrea BH, Wright ME. Satisfaction in childbirth and perceptions of personal control in pain relief during labour. J Adv Nurs 1999; 29:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/11\">",
"      Marshall KM, Baker J. Are patients in labor satisfied with PCEA? Nursing 2006; 36:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/12\">",
"      Saito M, Okutomi T, Kanai Y, et al. Patient-controlled epidural analgesia during labor using ropivacaine and fentanyl provides better maternal satisfaction with less local anesthetic requirement. J Anesth 2005; 19:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/13\">",
"      van der Vyver M, Halpern S, Joseph G. Patient-controlled epidural analgesia versus continuous infusion for labour analgesia: a meta-analysis. Br J Anaesth 2002; 89:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/14\">",
"      Brownridge P. The nature and consequences of childbirth pain. Eur J Obstet Gynecol Reprod Biol 1995; 59 Suppl:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/15\">",
"      Burden RJ, Janke EL, Brighouse D. Hyperventilation-induced unconsciousness during labour. Br J Anaesth 1994; 73:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/16\">",
"      Ralston DH, Shnider SM, DeLorimier AA. Uterine blood flow and fetal acid-base changes after bicarbonate administration to the pregnant ewe. Anesthesiology 1974; 40:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/17\">",
"      Peabody JL. Transcutaneous oxygen measurement to evaluate drug effects. Clin Perinatol 1979; 6:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/18\">",
"      Reynolds F, Sharma SK, Seed PT. Analgesia in labour and fetal acid-base balance: a meta-analysis comparing epidural with systemic opioid analgesia. BJOG 2002; 109:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/19\">",
"      Bergmans MG, van Geijn HP, Hasaart TH, et al. Fetal and maternal transcutaneous PCO2 levels during labour and the influence of epidural analgesia. Eur J Obstet Gynecol Reprod Biol 1996; 67:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/20\">",
"      Shnider SM, Wright RG, Levinson G, et al. Uterine blood flow and plasma norepinephrine changes during maternal stress in the pregnant ewe. Anesthesiology 1979; 50:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/21\">",
"      Morishima HO, Yeh MN, James LS. Reduced uterine blood flow and fetal hypoxemia with acute maternal stress: experimental observation in the pregnant baboon. Am J Obstet Gynecol 1979; 134:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/22\">",
"      Lederman RP, Lederman E, Work B Jr, McCann DS. Anxiety and epinephrine in multiparous women in labor: relationship to duration of labor and fetal heart rate pattern. Am J Obstet Gynecol 1985; 153:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/23\">",
"      Shnider SM, Abboud TK, Artal R, et al. Maternal catecholamines decrease during labor after lumbar epidural anesthesia. Am J Obstet Gynecol 1983; 147:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/24\">",
"      Scull TJ, Hemmings GT, Carli F, et al. Epidural analgesia in early labour blocks the stress response but uterine contractions remain unchanged. Can J Anaesth 1998; 45:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/25\">",
"      Hiltunen P, Raudaskoski T, Ebeling H, Moilanen I. Does pain relief during delivery decrease the risk of postnatal depression? Acta Obstet Gynecol Scand 2004; 83:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/26\">",
"      Eisenach JC, Pan PH, Smiley R, et al. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 2008; 140:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/27\">",
"      Zaers S, Waschke M, Ehlert U. Depressive symptoms and symptoms of post-traumatic stress disorder in women after childbirth. J Psychosom Obstet Gynaecol 2008; 29:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/28\">",
"      Soet JE, Brack GA, DiIorio C. Prevalence and predictors of women's experience of psychological trauma during childbirth. Birth 2003; 30:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/29\">",
"      Beck CT. Post-traumatic stress disorder due to childbirth: the aftermath. Nurs Res 2004; 53:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/30\">",
"      Petrie RH, Yeh SY, Murata Y, et al. The effect of drugs on fetal heart rate variability. Am J Obstet Gynecol 1978; 130:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/31\">",
"      Mattingly JE, D'Alessio J, Ramanathan J. Effects of obstetric analgesics and anesthetics on the neonate : a review. Paediatr Drugs 2003; 5:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/32\">",
"      Ranta P, Jouppila P, Spalding M, et al. Parturients' assessment of water blocks, pethidine, nitrous oxide, paracervical and epidural blocks in labour. Int J Obstet Anesth 1994; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/33\">",
"      Olofsson C, Ekblom A, Ekman-Ordeberg G, et al. Lack of analgesic effect of systemically administered morphine or pethidine on labour pain. Br J Obstet Gynaecol 1996; 103:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/34\">",
"      Bricker L, Lavender T. Parenteral opioids for labor pain relief: a systematic review. Am J Obstet Gynecol 2002; 186:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/35\">",
"      Nyberg K, Buka SL, Lipsitt LP. Perinatal medication as a potential risk factor for adult drug abuse in a North American cohort. Epidemiology 2000; 11:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/36\">",
"      Ullman R, Smith LA, Burns E, et al. Parenteral opioids for maternal pain relief in labour. Cochrane Database Syst Rev 2010; :CD007396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/37\">",
"      Caldwell J, Wakile LA, Notarianni LJ, et al. Maternal and neonatal disposition of pethidine in childbirth--a study using quantitative gas chromatography-mass spectrometry. Life Sci 1978; 22:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/38\">",
"      Kuhnert BR, Linn PL, Kennard MJ, Kuhnert PM. Effects of low doses of meperidine on neonatal behavior. Anesth Analg 1985; 64:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/39\">",
"      Nissen E, Widstr&ouml;m AM, Lilja G, et al. Effects of routinely given pethidine during labour on infants' developing breastfeeding behaviour. Effects of dose-delivery time interval and various concentrations of pethidine/norpethidine in cord plasma. Acta Paediatr 1997; 86:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/40\">",
"      Evron S, Ezri T. Options for systemic labor analgesia. Curr Opin Anaesthesiol 2007; 20:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/41\">",
"      Kan RE, Hughes SC, Rosen MA, et al. Intravenous remifentanil: placental transfer, maternal and neonatal effects. Anesthesiology 1998; 88:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/42\">",
"      Lavand'homme P, Roelants F. Patient-controlled intravenous analgesia as an alternative to epidural analgesia during labor: questioning the use of the short-acting opioid remifentanil. Survey in the French part of Belgium (Wallonia and Brussels). Acta Anaesthesiol Belg 2009; 60:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/43\">",
"      Hinova A, Fernando R. Systemic remifentanil for labor analgesia. Anesth Analg 2009; 109:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/44\">",
"      D'Onofrio P, Novelli AM, Mecacci F, Scarselli G. The efficacy and safety of continuous intravenous administration of remifentanil for birth pain relief: an open study of 205 parturients. Anesth Analg 2009; 109:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/45\">",
"      Hill D. Remifentanil in obstetrics. Curr Opin Anaesthesiol 2008; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/46\">",
"      Volikas I, Butwick A, Wilkinson C, et al. Maternal and neonatal side-effects of remifentanil patient-controlled analgesia in labour. Br J Anaesth 2005; 95:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/47\">",
"      Volmanen P, Akural EI, Raudaskoski T, Alahuhta S. Remifentanil in obstetric analgesia: a dose-finding study. Anesth Analg 2002; 94:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/48\">",
"      Balki M, Kasodekar S, Dhumne S, et al. Remifentanil patient-controlled analgesia for labour: optimizing drug delivery regimens. Can J Anaesth 2007; 54:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/49\">",
"      Jones L, Othman M, Dowswell T, et al. Pain management for women in labour: an overview of systematic reviews. Cochrane Database Syst Rev 2012; 3:CD009234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/50\">",
"      Othman M, Jones L, Neilson JP. Non-opioid drugs for pain management in labour. Cochrane Database Syst Rev 2012; 7:CD009223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/51\">",
"      Rooks JP. Nitrous oxide for pain in labor--why not in the United States? Birth 2007; 34:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/52\">",
"      Rooks JP. Safety and risks of nitrous oxide labor analgesia: a review. J Midwifery Womens Health 2011; 56:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/53\">",
"      Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. Am J Obstet Gynecol 2002; 186:S110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/54\">",
"      Istaphanous GK, Loepke AW. General anesthetics and the developing brain. Curr Opin Anaesthesiol 2009; 22:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/55\">",
"      Reddy SV. Effect of general anesthetics on the developing brain. J Anaesthesiol Clin Pharmacol 2012; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     Kronberg JE, Thompson DEA. Is nitrous oxide an effective analgesic for labor? A qualitative systematic review. In: Evidence-based obstetric anesthesia, 2nd ed, Halpern SH, Douglas MJ.  (Eds), Blackwell, Massachusetts 2006. p.38.",
"    </li>",
"    <li>",
"     Likis FE, Andrews JA, Collins MR, Lewis, RM, Seroogy JJ, Starr SA, Walden RR, McPheeters ML. Nitrous Oxide for the Management of Labor Pain. Comparative Effectiveness Review No. 67. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 12-EHC071-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/58\">",
"      Klomp T, van Poppel M, Jones L, et al. Inhaled analgesia for pain management in labour. Cochrane Database Syst Rev 2012; 9:CD009351.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Anesthesiologists (ASA) Committee on Obstetrical Anesthesia www.asahq.org/For-Members/Clinical-Information/Nitrous-Oxide.aspx) (Accessed on April 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/60\">",
"      Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology 2005; 103:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/61\">",
"      Marcus MA, Vertommen JD, Van Aken H, Wouters PF. Hemodynamic effects of intravenous isoproterenol versus epinephrine in the chronic maternal-fetal sheep preparation. Anesth Analg 1996; 82:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/62\">",
"      Colonna-Romano P, Lingaraju N, Godfrey SD, Braitman LE. Epidural test dose and intravascular injection in obstetrics: sensitivity, specificity, and lowest effective dose. Anesth Analg 1992; 75:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/63\">",
"      Capogna G, Celleno D, Lyons G, et al. Minimum local analgesic concentration of extradural bupivacaine increases with progression of labour. Br J Anaesth 1998; 80:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/64\">",
"      Gaiser RR, Lewin SB, Cheek TG, Gutsche BB. Effects of immediately initiating an epidural infusion in the combined spinal and epidural technique in nulliparous parturients. Reg Anesth Pain Med 2000; 25:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/65\">",
"      Mardirosoff C, Dumont L, Boulvain M, Tram&egrave;r MR. Fetal bradycardia due to intrathecal opioids for labour analgesia: a systematic review. BJOG 2002; 109:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/66\">",
"      Abr&atilde;o KC, Francisco RP, Miyadahira S, et al. Elevation of uterine basal tone and fetal heart rate abnormalities after labor analgesia: a randomized controlled trial. Obstet Gynecol 2009; 113:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/67\">",
"      Grant GJ, Susser L, Cascio M, et al. Hemodynamic effects of intrathecal fentanyl in nonlaboring term parturients. J Clin Anesth 1996; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/68\">",
"      Torvaldsen S, Roberts CL, Bell JC, Raynes-Greenow CH. Discontinuation of epidural analgesia late in labour for reducing the adverse delivery outcomes associated with epidural analgesia. Cochrane Database Syst Rev 2004; :CD004457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/46/38633/abstract/69\">",
"      Dufour P, Vinatier D, Puech F. The use of intravenous nitroglycerin for cervico-uterine relaxation: a review of the literature. Arch Gynecol Obstet 1997; 261:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4468 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38633=[""].join("\n");
var outline_f37_46_38633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PAIN PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      First stage of labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Second stage of labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADVERSE CONSEQUENCES OF LABOR PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurohumoral effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Psychological effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANALGESIA FOR THE FIRST STAGE OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Classic opioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Newer opioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Opioids with mixed agonist-antagonist properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Patient controlled analgesia (PCA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nonopioid agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nitrous oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Local injection techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neuraxial analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Epidural techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Spinal techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ANALGESIA/ANESTHESIA FOR THE SECOND STAGE OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Continuation of epidural infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initiation of analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pudendal nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anesthesia for urgent situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/20/7499\" title=\"table 1\">",
"      Consequences of labor pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/25/37277\" title=\"table 2\">",
"      Analgesia for labor delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37574?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/44/38601?source=related_link\">",
"      Nonpharmacological approaches to management of labor pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_46_38634="Fixed drug eruption with bulla";
var content_f37_46_38634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67733%7EDERM%2F52192%7EDERM%2F86671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67733%7EDERM%2F52192%7EDERM%2F86671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple violaceous round&nbsp;plaques are present on the skin. A central bulla is present in one lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On dark skin, fixed drug eruption presents as a dark brown/slate-gray patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38634=[""].join("\n");
var outline_f37_46_38634=null;
var title_f37_46_38635="Clinicopathological criteria for NSF";
var content_f37_46_38635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinicopathological criteria for NSF",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical findings: Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patterned plaques",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint contractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Cobblestoning\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked induration/Peau d'orange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical findings: Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Puckering/linear banding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial plaque/patch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermal papules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleral plaques (age &lt;45 y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Histologic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased dermal cellularity (score +1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD34",
"        <sup>",
"         +",
"        </sup>",
"        cells with tram-tracking (score +1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thick and thin collagen bundles (score +1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preserved elastic fibers (score -1 if",
"        <em>",
"         absent",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septal involvement (score +1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osseous metaplasia (score +3)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38635=[""].join("\n");
var outline_f37_46_38635=null;
var title_f37_46_38636="Etiology of mental status changes in children with cancer";
var content_f37_46_38636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of mental status changes in children with cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        CNS tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metastatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cortical irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Meningitis and/or encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inadequate CNS oxygen delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral vascular accident",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperleukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased intracranial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacologic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyponatremia, SIADH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intracranial bleed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Somnolence syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; SIADH: syndrome of inappropriate antidiuretic hormone secretion.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rheingold SR, Lange BJ. Oncologic Emergencies. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38636=[""].join("\n");
var outline_f37_46_38636=null;
var title_f37_46_38637="Rate change AV area progress AS";
var content_f37_46_38637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rate of change of aortic valve area during ejection predicts progression of aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rate of change in aortic valve area (AVA) is established as the ratio of the AVA measured at mid-acceleration and mid-deceleration to the AVA at peak velocity; an individual with a slower rate of change in AVA will have a larger ratio. Among 84 patients with asymptomatic aortic stenosis and an AVA &ge;0.9 cm",
"    <sup>",
"     2",
"    </sup>",
"    , rapid progression of aortic stenosis (&ge;0.2 cm",
"    <sup>",
"     2",
"    </sup>",
"    /year) was associated with an AVA ratio &ge;1.25 (p = 0,007).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lester SJ, McElhinney DB, Miller JP, et al. Circulation 2000; 101:1947.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38637=[""].join("\n");
var outline_f37_46_38637=null;
var title_f37_46_38638="Epoprostenol in HIV PAH";
var content_f37_46_38638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Pulmonary vascular resistance at baseline and after long-term infusion of epoprostenol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 311px; background-image: url(data:image/gif;base64,R0lGODlhGQI3AfcAAP///wAAAMDAwEBAQICAgBAQEPDw8ODg4NDQ0CAgIDAwMGBgYFBQUKCgoJCQkHBwcLCwsP8AAAAzmSBzOf+ZM2YzZv9AQP/AwC58Rdbl2/bz9v+AgKzLtf/MmcDN5kBms/L38//mzUqNXnBAcKCAoINZg3SohP/58+Dm8/+zZuPZ4/+fQP/z5hBAn+zm7PDz+cazxtDA0JCm06Cz2XlNeXCNxv+goP/ZsyBNpoCZzGCAv9DZ7P+5c/+sWf/w8OTu56mNqc+QkP/s2b+AgP+/gCYzhV8zacDDyf+mTV8gIBpdLv/Q0P/GjUwmTDMzf6CGbFBzucLHwxkzjK9wcP/TpgADCbDA3yBGkxApXBJXYxA1goBfgGlzrDBZrJy7pT8AAIZzhv9wcJKXk2ZTZoCWwjyFUlAQEJC5nBAsZQY/h++wsGZDZiZfNlAwUGafd7OZs1kzbBMzj0wzcjtbRd+goJCTmTA8VmxNfyY2X6Kno29WPAwzkiYfTHJNfB8zif/fwJmAo4xmjBA8lQYzlQAvj9nN2QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAZAjcBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOMKNSBAgAGCdQvmlcu3r1+ZBxIEGIgggOECCAAgKHA48eLGfyNLngySgOHBAhEQELAgAAMADAJAgOAZtGjSnymrXs364QEBhg2iBhCb9uDatVvr3s0798ABAQTYFhgbN2beyJNL9m0gdAPimItHP46wwYDr2LNr3869u/fv4MOL/x9Pvrz58+jTq1/Pvr379/Dju39ANPcBBQEe5A09ujT/2Qq9VpcADigw4IEIJqjgggw26OCDEEYo4YQUVmjhhRhmqOGGHHbo4YcYOjCAUJZdRgAAJV6mGGMBILYiZA8JMKJyNNaIkYxCCVjXAQDouBcAPwoUpEM42mjkkTHOuFaRSDZpE10gRqlhYnopqRaTTmYZkwAFyOflegpYKaSYaGGp5ZksmcmUmmqe1SaacJb0ZlJskummnXHmGdKcSNXZFp8cGfCAYQlAoGeWgBrlJ1uJahTaZQFQeeiRbA7okHWSVkQXjxotuiSeHR0AqWELTIqkmpC6eFAAMwpAAKcMwf92ol6hzeoQXXcd5OmVoHIE26i9mqobqoM5UJoADFznAAANBJDAq67yeMACAyyQmKsQUGtoZwPYCl0A3i6U4nMG7ZpWoxiJOmqpwtpILJCsorgAAcA1MGiXmgV3QAEKEFBAASi2CFwA9zlLpmXhJvTrZZmOWW6wYqGLUWeQKtBwu7wRSwB+zxngAAP4nRhvwAQGMC9wrgYHwKB1gXsQwg6laFjC5pYJ8UYPMDaAZgUsi3FyxF5HrgI9GyvyjJalPC8BryZNsqwvu9yQzAH4jBeZEnuVdUcCJMBArj8PS6ZvtCUgwKAim31A0oUpAMHZ+QqXNGwMGIpXZwsIx9C+lxX/APZANd/pkgELFGB32Ky9S1CzrLpcYtwAQIBfAAqsrbLTwAFM0KgOIZDsArBe/fCfN2NkgwWop27BQBAU8MDfiEu2NVCBmzX7RBtEoPvuERB0wAAJXBx7X7f7VHtZxUeUO++6G2T08LKXPtTxZCUP0fLMH4SAApVD75f1O1E/FvgOYc97QjmT631c5OckfsTSW2T+7gTADrjX9q/Pa7p22fR+WO1jyPx0N4AC1O8gzSmA3vTHKDJlx2oGIQC5nNaQtS1wII8KXqewFr+uBHAhp1Md6oBUONAdpAGuyx8Dqzc2cIUsMz8aWUFeE7oe6Q1qBXlWaBLQkDCI0AajqxLp/2AyLZPVsEcDsNgKz9VCeI0oRQX43WVSJpxBkSpgk1OAbcg2EC4exALM20AQRddAwODtYpaB4BLH10RjlUoAB0AA2tpml6SRZlmhsZx+8FOyvJ3QZA0BI+/EKMRCfoomBvDXAC6omDAdcY1aayGheIRCfrlsZEmjGhWfJjW98EuFBRHk7ghJxlLuryaJ7NIFBWU4SMLPIIaJoRahhsngNMtnBkjk5YKDw8WxCpShDOMYAdfBmSDggpohgKSSuUymCU8hH+yIARqQgASoL3IF+Jorv6K4geCngC4TzCKTZgD8hCk4TkuaqPiFl1Ex8ovCNCQxc4TC45CmmqKJnLMEY/+oe/ITItH8CDWtOZDmmG2bHjxYuBK5mc30iGl0eZVAIMA0Q0ULSBJ1FQTXxjSmPbIgNtiASEV6gWE6LCgp8mak2gYA/CCApS5laZJ6Yp1n5coBrgtKMWVDAAcc8QAOIMDhEDSpgNLkfzfJjXGGM5ylztR4BTzgfZTIk7qJJjUQsdugiBZF3/0LP/TZohfPZNSZINUmSp0OU6UDHXEBKygyMiCP/KXGm0hxANIS6gMGcLiCeEwwADBAiwBgrLAKZFDLYsxdYjkkOJVVJmetSW4UK1iAUXawl9UckXZKRLzFMQEDACZMHmBO+sDmWS4tCAI6kwAH3AU2I4ItQVAGANr/GmYADHgnmh67JQ7m6FdwBEBnmAbI4VqmVMYF5FOHUkRrFa6vNRHOYIQDNdJ4y1iFamdsZVhbldGWAQToTFf1xFuYRFYmMjtRcwyjzfV65i7u1eZyibK2LuVsAaJ1yQKh1kvFhEYB6mMpgATCn5ZGarYqIy/WLNUQTF3EVULdyHm5Ut6TpBI/GgyfyQSQ2hnmLKcA4Kdzusssz9wTSP0Sb34pJckWPXNkF21If+Flooe8AAoK820ZlZJIwXQSJ6dt0TUN0gAtNrJFYQXOYRmjxIJR7plaepexPoMsZZX4Wa+R6LSqdS2haku4rPLWa0osvRxIQAYImfBWKrwSalLu/6Nb+jFC59tW2YaXXgGwl8Ditq9+/StgXTJMwUBLZAa0siEoaIEEWvACXen4kE+hZs9WrJIZz1nGLdxYngP7sRfWso943iTLLL0yog05ITqQgKpr4GiT2kwqXTMgpS8dvhYKTSBEc8DzPn3cjlpObryU8+aokxAPqPrYKHA1m+nE2Z+sV9a0VlQTN2c2tJUNjmyj3NseALm5mZggBADvDhvShWOr+gPKbjZWlg2T1pEKztHWSTcFwjjgnOhxTpOcYSqXTu8OlnU+3hlDZmDuY3tAnieFNFV+Z0kTxvsn7O7IDjxA8Yp7INmmTPgpreLGEur24f5Td61dLTisbG9niv/8OMghK3J5P3rjV2FlA1LJ15XfJOKVfjkTKZzNuwz01DbXb8vdp/NXc8Wgevt50HsbFTVrBec3QaFha3rApaep5TE+atFL7pWpSiquVbc6SojFXhUOIKwObggCBgD0wiT4Rlv3yLR83K9ZMz0sacSLoR8Ab7FzrYWcASRQnakYytnlNblqgATvQkPF88iNjDSAj1VeEBUIRAMuaDXCP2KZbDItNIfuCdR1ggDQhq65ffd7Rt5lZ9AyRkZTJCfRgKPFzh9GsCoiyAMSwMeGxKACJNBACUaQ+c2zGVx/O0CyID70pbASus2FsurhDsvgDLdHCHDA9T/drM2EJl/PCU3/y8IFG9hTfiDCr8AIgK/5jAu0Osw3S+vw69eUT98jZDfZXTrDgO0jDZ2Ugx3dFmzhUkDgRFUL4QIVUAE0kGZxhzzN1xRIZxA0d373B1DT1kVa1H20oUW6JACkQX8Q8Guc9DqLwzSC4XAKkX7rRwLtN08hIUdgFlpEMXo/gVMJw2m8B3QXGBHzBmYt4jIDI2qQMoB2wSIHQVsM8XvBN3zF537lJSOFQVrsIhQ2+BPbg4AF8XMXwDy6U1I9uBCVUi52EVxAIhyIJxBQwnj9k4Z0ITzHRGmFcHmWl24iwWEiAiQRmBJXCBR0lRBFZgZeGAFgGIY51nQPuHr7RlhYBVd7/9h0+JMQdDCIhWiIL9gUTncrluIAFghkjxgVhBN6BdGFXliJlrh5S5GJANWJRAcXrWOCo0iJp+iAiEhyHsE00hYXv5NhA0GKzJMErDh9fUgSqvgQuCgSItItN2VlApGMdSWGn1gVz9OLgzgF+DKL7icRaRhdiShhwTgRg8IAoVEqliGOjuMZtYKBfZGFnOIDF/CO8HgBPpBKKniKavJACSFBAkFBe+NQBLF22GFYDcEBh4iKQgEcnFgagnEAosJDC9mQ6ugX6bM3hRN2hqgxL6QYMWQnNDRDNyRnsNElZ/cQJjABJkCLBukROHUZj/gY/7JYauVUCeEjefgXXSNfCv+xdgXAg6rHevECRVIUS05jRYBkGVkkVu1kIKk3ECU5ASZ5iXpoEgJzHQKZEYWVgmt1G2qlENaBHWEiGQlEIIJhQGmmANkVhlIGSHAkR+BCRx94R6ahRxwWHJDXTpfxjAbRlE75lMYXjQfxLCERG7gXYgQDkQ/pLBEpGfUEKTlIb6D1jbSWfwlASV91Sf+XMpCySd62UDzyKwzxAxiwl06JAT/QlybRNR3FkxQBHOb4ROh4jubYmCg5GT7WNwpBj0sZbcQiS/ByNPtoS1Wjhh/ISeR3Lf+2EBkQmqOZAXZYEpNzW9K0VwPgWs3IjIRlnZulGqMyVgRBOMhnFR2pPf3/UxU/+E2McSLiREXlFIAACGxw1CJG9puXoZoEkZwTgAHM2Zwk4RkDIn0355dbUZuH4RAMJ5tIkSsUo1wF9ZzPsTDcpRRqcowFxTSugoYQFWMUFWEXtaE91Z2Kp0wQkQFlkJ/6ORIPUIVWCKBaQRqpAl3QBDz0ORObQlFwBgHXUXha1GHNmB+VBS/Poo+YqKIvUYwPMTDQSTtCmhUQIBit1To4yRDUtEg4ATMhWUDjNaEJUADWEjD39mO0hTKnBaRBWosp2RHSSZWOiBwTaIzZlJsooSJQc0vg5izU+Ztd6i1fykuuVxpjChVESqDCgStpmhw4CBGCwqM0QaUu01+W/9FaYAMzMPMb/rZAg9mnT/GnDaEAnyF5KCp6SRoWXgcRygdt0eUynQFdPaaljkE5BpYYI1lYPdoAnNioTjGMI4GpDJFg9DKoNPKHGEhQRwUpnUoQNjojCcou8bKehvEcxgIja7JgjVUdAncRgxejB8ECJSoSPUNgjeipRnKTdhc5vAeZdwguAuCfgTUQ4QkkyzSeNkSuUFV9zloQMCZRMiZszdIl3coQLMADKZCtIdEZ3LNpSHokoeiiDIFTeBVnBrpjw0ZYx5Is03ll0KJl1LKl2PJl3CJmzhKuJ9ABFEAB/2qaJeGdIFawSPKK4apL9Dc4Zkg8TWRnJ5Nn94Jy+v/CL/4CMJ03MINmJcZCNMHZEDewAiErsgDLdUeyi+hqENNCqgyEkZvmMSBjmb8JaigzlARYEMflbn3HAilQtCE7slCYpOH6n1oyjRGhk9YqLEHDdrhWNFRLMr3mUf02fgXxPEqoEEMLtmILg9nYERuWi1pycm6KF9UEr7uVgcRRbZekNtnmNnBTt3TTVw3ZOn7TEB9btH2rcZz7ETlDp4VrVp96ECdwAmMxkROBQtM6PD9Yb+cYKfmWRSSIOcfpmM6ytAPhtUZLsiRhHeyFsC63EkMbAtXTcxOBm6w7uiMRAkRwtCGxNkyKu3d3EiHQAyFLvGQRlhTRtBbZLrZ6h93/CBIQkFvxZxL9CrbYWxZSVxEMh5cKRqZ/6xEU9VDSy3Il8bFEi75oEaoUwWFnybbKm3O26BGAWVv7OnLLiwRgW7TpexZ5VxFRirjK8b17Er7aWJW0oTe7irIigb8LTAENfBalR4MUgbyHwmFSksIVUpPx+xAGAByh1TpkkgD4VU7DisAkwQJEsMB6IMFW8XwW4Z3deyYA+SVGfB4YTD6ME4T5EUGZyaslUb1F+wRaWrZKWsUWMaoNi40fQT4bA7GiuDi4BbzBmxJ7GwKjurZd8cIHZREyAqxcLCcttzEl0wDnikBlaMVCtxIfKwRCAlr1uxWFehERHMfEOMfbSSaM/8NhGIzDL2EZsIgW7IgR/sIAoWvIiQnB24HBvGc2G1y+McFwZCwWvhrEgxLJmCxhLYcAqRcci7RXILEjgMNI0QqNNbGkC3sukUitFanHqQyVEmEZbpsQNOxnjUzILHIij+FiL8LMdBYTujTEY5FAo5wkcPzLbox1j6KqB8GiLXLJYvhmPWIa/fEZ/8Gn2XkTa9fGaKGyGbGkBoLN2awRQDU5N6wZPuUReINbPLJUMolpOoFClpwWv6OFFqGw4CzP0eRmijxz/ecRwLEAoTEi/ryVCtNR4RXAx5szW+wVkYoRLOvLmNw+nMEi25pD2mcY7ruaKsNWTWXRaYbR1CJ63P/jw1NBuPTcy/L8zMF8GQzAg8ERJrDMEUZTGDx0zuZ8GugM0D6BUy1rFkCsEWq700xtEQSAZQphQODyyRqhrC6yzF9t0vVLwS5saCvNTcbbKYcLACKEOktA1VF5EStmRRx2wxgRh3hBy+RK1gDFe4EccwzAzhmhurJI1e1zL7LpMRCQSH89pBq9Ef6CymSBU8dcwgRQ2DtNPt78ds9aFAynxlnBvxqB2Qo9xwmQSwVMEAAm0ub12B2BywlNFaWMEYMYBKxtdV5sIHV9xyrFzdPj2tKEMLf9FCM83IOYBJ6Rz7/sxYmsWoVDp8M9dsAtd8BTzUf3XLRditNkaArAbSP/3XJdmR2NPE0DU4+OjBQCHdtS4c4V0dYW8Nass3tautjYOHoHkDM2Ld0SyNFnwcaNnbYFwirKjZbTHd1yTNxmmd9PgbYjsd0FkAD60YPs9gDK9OAGfprTTRJOfeFKMckncTZZugAz15Oju5OGdrLxCoqFc9ZcgbooAVQwPOA2x27B4TVc7a1T0TXxjDy7nBLTVDgQbt2QxG5eAy5DDcpTEdkcfqCGpuAVAeLZNOK6ObrGEkUQDsVTkcZmIXVLHhEwTjkO8N/eq7ysLKgcbBVds7piUdBiHijZ8uAPIOSIw26CsjN1g+VVEc1dbhQPLBNyRDQ/vec1wm6PwhkHXMZa/7GLcn4VOE0TQPVfILo+NC4irpLhE8HXKyHD6u0UUY1Kb07Di+5Yoysai4RbeJ4VrNTRWDF/gn7XpOUZDbDpNMJuhfPgBIvkXbHOTs5jgb3rIHEADQDpbQ40o/tsld2KYoFTAz0Wg8wT2VJNCxDqg27pKS4WocjiJsc9w44SmoEfDCDjUTa6i/mgPIHpkFXTZPGH981lOwHs/+Xd4W4SOoOmZz7ZWBwxXsMihiHtLQEB8h3trb5zJYHip77mhgbaU6Gsl8FDQJF93g7uAOCL5zMZE27XOK7Lau4V+j5Fsq4SDt7dCyTxu0MZ7Gak5H7eaAHJAd8Tz8mSjCGSTGPH2/9eEv4e4g2gBoNI8qN7piPpEVBCGISXGUHP02eh6F9BNUryGhl6HQF3dhJUyy/h8F+Q8xRf7CRBMRO1T/nkT/lE9O1sel6RoAqQX1DyeUm0b9XSU3Wx8gwh8s1T9SZxa+KbezHFqnUfn1XtFocqzVZxTNteF0FFLZMDWuC1Ge5KEm7fO5fK2wdeElbk2xthAFq9lS7NnfLJkiahAW8gEDFQh0Wh67txTIonnYdxHRX1shuR+Jz+nCR8q8o7TSziNhsBMlnZVv8cK5+afoDABern+UWR3gjBAiEsGce09OAkkhQu8xXhjhcwBEMQBO/oFI9yGRbvK6MrRz4mThuxnQD/kFndHwC5VLu4XxK/VwFOMAhGUAFAkBShGC4nwAQU0AE1ovRm3/TzwomdWHrUjxQ+AhACBAQgWLAAAIQJFS5k2NAhAAEDHk6k6HBAgAQPDgA40KDiR4QCBwYQAGBBAAIEAiwwiVIlS5AQJcakyRAGHAkSimyp2dPnz5AKFJQEQGUFBQodgC5l2tTpU4QGBKZcMEABQQUDFqQUaCBhgoIEPUKVKtKsQAcp1a4lMMDtW7hXw84tANftXIJQJ0bUO9EBhL4N8wIwwIAgA6+FD3uNyTdwQxh+ckrgE0ABAwICNj7m7NBBgSc9kCJV2tn0adQg0RKoehGj67AJ2KZkYNcu/965tuFinq0WwtmzNeUWZJDasWngAhCk1nvcdAw5kyVIASLAwYMBBQJozcyY+VMWPEaPLv3d/HnzCBzglT3bQXKR3tGDRKCdYIHlqJ1zxj1z/s/9ONNgD+kkwAMzoqRyoKoA6nrgPfn+o4iFo8YjTUIMM3zKvoIe0PCxA9oiIMLOAgwspQS2IiCjD2kyMTAZCpRAkDoWuEqBBd5L6AABWLsqgQEIaICoFhM6gQkLkypySSYdaiAsBUhscsqGXgyMJIQIKI5Kh6yE6oUWZJQgh4SsYwCsAR5oID+EEIBAyx8xg4BNDYVIYbzyuNQzQwEeYMABKffk0ku9ChgKgqwEXf+IUKdqmCyNLCZrAQWGpGqrgLoIgGCzMhtoC6zLMuP0vz+QuFBRVFNVFT1Gn3qyIMBUbfWpDDCYwISYDnjzogQQJNE67LTjToBAT+tghTxXVXZZZpma1SkEUqIT1WeZqnUCbHHtCYEGHrgxRyIVspRBByFk7oQQmlV3XXYpqvanQItt8t2frsU2W2cXRFPNaXfskYEfgxyyXYILNjgwenuKkiEEtlQ04ZpAsPXee894ylIGMA1y04fc1BJUOfs9eGSSSw7Jv84wJSA/BE5yWFCIa+KAYmyVyAPEXTHydS9PBwB1K81ociGhoU02+mgNY47JgJPCKoAAWVE2beZ7RRD/IwHZ5GWKW28xApciBYPdDtxiVRiBBABIGEEFpNt2+zulaeooJQi0nlfqqbEVAYSQDFsgXM6sWwBUfisa96JyidRghAoqoKFxGt6WfHKE8ab8o7hl3nuhEA1twG6nMEZT01Ef4hHO1wgYo/HG1778ddh7yrzt2V3NTiPzdL20gJ0/8piBJlhf4wGuBIr9eOQVqv3o5Z9qua5Yz+Oa168rIoH1xtsgADurCnorpfeUS358o5s32fyLHcB6RAkFv7FwhjQooQIjnGi8hIbK8pQ1t8Bq0C0VDSlo5CPgqtBHsgNCRQB+E5l5RLedB3AMIRq4Qxx00gcN+IRH1qGNW+wD/6Q00a0rBSRhixJ4sBNC5QAP8FyLdJedTB0hTDlpwQseg4CppOQtBclKkIoHuKXIDwYAgEEJMlhCJKawYErUSwMUUADcFYlraCiQDtBTljdtzy1yqcsAeBO+BjZkfhW4XgWMiMQSMrFdatRLywLAgOh9CAVissMC1uRCgeyvNf4DYQAFwqkysg5taCQhG9dlSL0YQH0JANSHPiCmK3wMghKcEg45qKW7YGUAwWtcIAiZRssVMpSoggADMeQBMeVkBlHZlca6IyswYK8CQ/wkARHZrFuCiIUKGIugOoIdnelIUIxzXOuOWMvk5XJZyuSME59Wuj2px0aWyVEYM2Q2tP+pjW0lQ8EHkOmiUdoynMt0GRAfJsk0NQCaGCoaANpJMihIwAPfVM04x8fM0xhgRYwE3ZQM0MpM1Y2eS0GlBHAw0IrgM2pGg0B2FmBNRekKmL3KDEJpgoPJyMCiD1EoWbgHNYQ4wC0OSIhIB0BScCJthXXp5bq4NU0cOQCi9DQAGaRTw41WyZ4Pq4t2oKYSBhjmp28UakrbZgBnEmCduHTAmSCozlrmUYvZCUAVCFGgGuSUIR29mFcgsB0AgOUAB8BIWAMw1rI2ZqcGE8BJ/jYyS8FwY0tt2wY7KJes8OY3G3GUjHagVeWtFVUqgdpg8mLYAFBkg2gRrMFChLXPlUz/orzqHQo5yD3tdJF4ApzIHMXkTcCerGD1WRhiAWDaiTQgLo0dmWoLsAC6Euyl3xKmTzSKHh5lsTb+y2vxYvuQHHxAuMMdLqVCy1VXWYYxYiVrAsyKVueqFXkHWABL3Sa4fd0RJDuQwCofU5a0cO8+bknJkGYa2r4gtymvegsAgFrU96LEqMhD6vp+azCMuZKSDXkkToGCwyz2T5MqGiF6k8ZaKqkWLiEdaUkbPN97utWcR3uhzl6ZECtMhkxgW01rCAJCEZ7XwO1D8OXUy6THJiCyl+MabY+A0ckYF4f78yBBAEiA8PVzxEs6sZ563CTXRhF2gsNCgbTwYS+GeMdL/ywx5X5cyeoOII6XQ8EMpTPPJZevyZN7MpUUuT4dH0wHYjpols+3Zcl12cd+m/APSlZQMXnXzCNTM5PqrKfO8VI+M+PAnP18njsXKdB7CvJGqDaBPv9Z0acZ9IcaHc3qzoFmiV50pdOL5rc9WlBeoBm2KG1pUDsL09cd9fhE0OkJKAGEvNHUH0P9aneVGmma3hMITk2xvYlkf22psY3dQjwcxwfWi6Y1iXds66rx7SNl6RFVdohk8opQfOcBgRsyMGx2Ffs/2tYTsjfXRoFkkdc+4+GNfxhmiiAbA9fGNi5lzbx3jw8EJlD2eZidlqnCpos+FJJIPoJsbK273cziNv+r4j1wuYVbLbXpniaTXLwo3PpeAkf4QqN68IorUKpTZQOqMZDxVBUc0BgHeWfsRbFPl3xQJKczy1UemJMj+uUwczlbaz5zqNgr5Ti/GzJFjvBa7Zzndr45wX4+dKQ7uuhrXHrSnd5ynzf96VNnetSpfvVPHp05Wsd61x/Ddf1I3etjp/nbpCLiRYmd7GufEtgr8irl1sTtbKc7hI2mHQM8IAAolW7d/U5q2oF1IKyd+98Nr9PAS2TwFVEJbhz/eMhHXvKTp3zlLX95zGde85vnfOc9/3nQh170o7e82rcteLDaHTWJNc8tU3Ke15tnABPuDOu/E3u4qd32xjH9f/D/rne+1/M8u+c97EF6++MzZ/bDN/7ImZ97t8F9Yao/DfHD3nzz4F75tOcP9qFvHusjp/f/ObtPbhl+8XufOdpPzfLBr/7iv//7Wde987Of/NSwHzXu/w76O6N/Rqu/+SMkA0C7p+C+7zJApxir82DA9EC3pkDAwHDA7yhAQHMgBTw8DdxADuxAD/xAEAxBERxBEixBEzxBFExBFVxBFmxBF3xBGIxBGfS7vBuAhpkykwkRtZBARWkAxHgiHlwW4qmPBIBARUGAAaCuvVNBwyCJBXgZkzEADpEvdmGAHMEIBSiZAvBBTPGQkVEfBMCIADBCv9u72WuLwPsbV2OXIKmu/4EoGZKgqPE7jbZ4kjAMwg0MgIaKCCgsGQPAEoOxESD5qpLpFZTADpJpgLoYQ0A8weoqALBoKaPJih1slzDUQxspmfUogANgEbgCCzUZwxRUDCh6m7nAv2Y5gOUYIJJBgAOQCjIUFKkAAATIwBk0ILO4L1TZNVQkGEVSC0lcorXQRQ5smLfwQnZpALEKAJGRCmJUlMYriJKBjdRDobnAQw30Hxtrlz8ECwBQAFSEO5hgwwL4DeMhGcsQCVsUFJUIH2JJwTeyxj8EgCDhnO1gjQAIRiGcw+8Ax6MhxBZkAGSULWYsSEl8Q4SoR3XxFL1bi5GhjfYQEhRKiddSi2fUwP8o+zWC0bcIIavMUER9VBVqlMaD6Y+DicawwMbDo0Z+TCTseKiGaJq4UxdLCg7LOot15JLFMotYvEUNUaqQEpk3WbFk9MIFKhk1CaleZBckjIokPEGl4sWQVBZA9MeoKImzuEgqaauh6BH/axapwBGBqI2RUQ+SEICvUskyjIiwaEmnQEmC4Ls3PEV2YQ86w4txLJiRPKsTJJaanLaFvIgeWgDvCBH3Wgu1bJJPsciReSwfaqSDaYCTqESfZBag5KhXrKh2UUWkccWjmcUVNMl2sQtJ/MOGahCt9LLWcIuSMUaNJJlxs8ET1I2BVBe6VJ7EWglGaheZHIyR0cZqNBj/uCOIxKzMIjkATlwUPdRDhVwXn+lJRYlHo1GJnDQ8BLgKAdhN/KJChbAP5Ay+ZnGALDwagTyaMIROv3uiAugTt3yKtwAL8JSJIXnKZNyO9iKZjEyTVjSUt6hOtmPOHmlPp2jLX8nFdoHLaWxLBLrGFCwAkYKAFHGb2zROCuUMlCzOJinFtGQItXBDgimlkzIakYIjk2mZNEFPthtRHCQ4UfzGpUSIfGyXr+oQpAyLFWUX5OQhFWyAz7FCo2tRq1QetOBOdfEir1AJOISawhDQvliRjRgIDKU7Rmqa+GQWSNQSZmQIBmVDLwTIkdFDhEDEhxzPP4zS/xSArBDTZLSP/7xMCMQkmPXICukcGcPoniplytfAFBV8Gpdg0qZwRsIok8S6TINhoTdCUX8yjFIsGWW0DP9kO70jCRxxrBU5voH4KndMzQrdVMP5C3161BbxwYI4PinEixdVFepaMARiOP2Eq9gEVbKrSVjFEAKYQsAJkZWgzHVpQpIcmSn0U6hYj5RMwUjdRufcjt9Av3c0GIBBmkU1mfVAVLZbxBWpzWVpQhxBv4Z6i6lUFQRIALNg1NkTiFldEgPgJWFDQZIYQy2xxOo6jFud0IWci5LpTWB1HluFx4YCmHtdCtUiUohYQoPJDodER3AsL9gMAGAjVBMknhntVmbhzIUox5McT/+jadXzaVEXrMW3wRpubZcnUdWRyU9rtUT+dItyvTrOFBFTDItTTRUEJRmWXNBhNUGyeqOCuFNO3dlaUomLmL1EMZpZzEqeLdqfQMN6RMPyyU2XNVqnpYlazQ4gARIK+6k3fVqspQi4DM6s7drpAo6UDbWGgi33+spsM9tmaRjiCFuvHaiRaJBoQVtl2dp+ZYopbJC2Hbh2VMbXkttVoVtrjJ4NzdthQ1LC8J/GfKJkXVDBbUTCFVtArA+/nVvLmNxVuduDeNxhY8UeKdGraE1eZQC21VzSLd0KNUw608wHKNmCSUrTbTeENJgZXQl6rNulgAtIlM3XJTbcGJmLAKZu1vhSvDDT3a0lyaXXg2FNAHiSuqDTN0LTv5HW4kWiJxHUkY2ulrDdpfgMq3jZ6TUw1OUI71WWaOGUBWBdHL2I8f1e9g05TW1f+I1f+Z1f+q1f+71f/M1f/d1f/u1f//1fAA5gAR5gAi5gAw6tgAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patients underwent right heart catheterization at the points cited and pulmonary vascular resistance was calculated.",
"    <div class=\"footnotes\">",
"     PVR: pulmonary vascular resistance.",
"     <br>",
"      * p &lt;0.05 compared with PVR at baseline.",
"      <br>",
"       &bull; p &lt;0.05 compared with PVR after acute infusion of epoprostenol. There were not enough patients at 24 months to determine significance.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aguilar, RV, Farber, HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846. Copyright &copy;2000 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38638=[""].join("\n");
var outline_f37_46_38638=null;
var title_f37_46_38639="Side effects antidepressants";
var content_f37_46_38639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Side effects of antidepressant medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anticholinergic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drowsiness",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Insomnia/agitation&nbsp;",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Orthostatic hypotension&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        QTc prolongation*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastrointestinal&nbsp;toxicity&nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight gain",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Sexual dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Selective serotonin reuptake inhibitors&nbsp;(SSRIs)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citalopram",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         1+",
"         <sup>",
"          &nbsp;",
"         </sup>",
"         (all SSRIs: see",
"         <sup>",
"          &bull;",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escitalopram",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0 to 1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0 to 1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sertraline",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0&nbsp;to 1+",
"       </td>",
"       <td>",
"        2+",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Atypical agents",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agomelatine",
"        <sup>",
"         &yen;&nbsp;",
"        </sup>",
"        (not available in United States)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        &nbsp;0",
"       </td>",
"       <td>",
"        0&nbsp;",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to 1+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        <p>",
"         2+ (immediate release)",
"        </p>",
"        <p>",
"         1+ (sustained release)",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mirtazapine",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;4+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desvenlafaxine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        <p>",
"         2+ (initially)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         1+ (after 1 week)",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duloxetine&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Milnacipran",
"        <sup>",
"         &sect;",
"        </sup>",
"        &nbsp;&nbsp;",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine",
"        <sup>",
"         &sect;",
"        </sup>",
"        &nbsp;&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        <p>",
"         2+",
"         <sup>",
"         </sup>",
"         (immediate release)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         1+ (extended release)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3+&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Serotonin modulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trazodone",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        <p>",
"         1+ (hypnotic dose)",
"        </p>",
"        <p>",
"         3+ (antidepressant dose)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1+ (hypnotic dose)",
"        </p>",
"        <p>",
"         2+ (antidepressant dose)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1+ (hypnotic dose)",
"        </p>",
"        <p>",
"         3+ (antidepressant dose)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0&nbsp;(hypnotic dose)",
"        </p>",
"        <p>",
"         1+ (antidepressant dose)",
"        </p>",
"       </td>",
"       <td>",
"        1+",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vilazodone",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nefazodone**",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0&nbsp;",
"       </td>",
"       <td>",
"        0&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        <span class=\"subtitle2_single\">",
"         <strong class=\"subtitle2_left\">",
"          <span class=\"subtitle2_left\">",
"          </span>",
"          <span class=\"subtitle1_left\">",
"          </span>",
"         </strong>",
"        </span>",
"        Tricyclic and tetracyclic antidepressants (TCAs)&bull;&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+ (all TCAs see",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        3 to 4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxapine",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clomipramine",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desipramine",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxepin",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipramine",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maprotiline",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortriptyline",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protriptyline",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3 to 4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimipramine",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Monoamine oxidase inhibitors",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isocarboxazid",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenelzine",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selegiline",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tranylcypromine",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Scale: 0 = none, 1+ = slight, 2+ = low, 3+ = moderate, 4+ = high, ND = inadequate data",
"    <div class=\"footnotes\">",
"     * Risk of QTc prolongation or torsades de pointes is also elevated with advanced age, female sex, heart disease, congenital long QT syndrome, hypokalemia or hypomagnesemia, elevated&nbsp;serum drug concentrations (eg, drug overdose,&nbsp;interacting drugs, organ failure) and combination of drugs with QTc prolonging effects.&nbsp;Refer to topic on acquired long QT syndrome.&nbsp;&nbsp;",
"     <br>",
"      &bull; All SSRIs and SNRIs&nbsp;are associated with transient nausea and&nbsp;gastrointestinal discomfort&nbsp;upon initiation or dose increase.",
"      <br>",
"       &Delta; Based upon reports of dose related QTc prolongation and arrhythmia, the maximum recommended dose of citalopram is 20 mg for patients at increased risk of elevated citalopram serum concentrations.&nbsp;&nbsp;&nbsp;",
"       <br>",
"        &loz;&nbsp;Sertraline&nbsp;is associated with higher rates of diarrhea.",
"        <br>",
"         &sect;&nbsp;May cause persistent&nbsp;dose-related increases in blood pressure (primarily diastolic) and heart rate. Monitor blood pressure regularly.&nbsp;",
"         <br>",
"          &yen;&nbsp;Agomelatine may be hepatotoxic and is contraindicated with any degree of liver impairment. Transaminase monitoring is required.",
"          <br>",
"           &Dagger; Vilazodone is associated with higher rates of nausea, vomiting, and diarrhea.",
"           <br>",
"            &dagger; Trazodone is associated rarely with priapism, which is considered a medical emergency.&nbsp;Refer to UpToDate topic on Serotonin modulators.",
"            <br>",
"             **&nbsp;Caution: can cause liver failure. Not available in Europe, Canada, and several other countries.",
"             <br>",
"              &bull;&bull;&nbsp;Gastrointestinal&nbsp;forms of&nbsp;anticholinergic side effects&nbsp;include: dry mouth, constipation,&nbsp;epigastric distress, decreased esophagogastric&nbsp;tone.&nbsp;&nbsp;Refer to&nbsp;\"Anticholinergic\"&nbsp;data&nbsp;for frequency rankings.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Created with data from:",
"      <br/>",
"     </p>",
"     <ol>",
"      <li>",
"       Nelson JC. Tricyclic and tetracyclic drugs. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg AF, Nemeroff CB (Ed), American Psychiatric Publishing, Washington, DC 2009. p.263.",
"      </li>",
"      <li>",
"       Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"      </li>",
"      <li>",
"       Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108(41): 687&ndash;93.",
"      </li>",
"      <li>",
"       Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric disease. Clin Pharm Ther 2011; 89:142-7.",
"      </li>",
"      <li>",
"       Howland RH.&nbsp; A benefit-risk assessment of agomelatine in the treatment of major depression.&nbsp; Drug Saf 2011;34:709.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_46_38639=[""].join("\n");
var outline_f37_46_38639=null;
